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Abstract 
 Charge density studies have been conducted on ten CB1 cannabinoid receptor antagonists 
via high resolution x-ray crystallography.  The experimental electron density distributions were 
determined from multiple redundant high-resolution diffraction measurements at reduced 
temperatures.  Topological analysis of the experimental densities was performed using the 
Quantum Theory of Atoms in Molecules (QTAIM) approach.  Bond critical point values and 
various other properties derived from the charge density, including various statistical measures 
of the electrostatic potential, were analyzed in correlation to the affinity (Ki) of each compound 
with the CB1 receptor.  The data was also interpreted by principal component analysis with three 
principal components accounting for 80.14% of the data variation.  Exploratory factor analysis 
was limited due to the low sample count and the requirements set for the inclusion of 
correlated/anti-correlated variables left fewer variables to analyze.  Correlation/anti-correlation 
was found between several properties and Ki.  Of these correlations, the most well-established of 
these properties by this data were the charges on the ortho-chlorines (correlated) of the first ring 
system (in this papers organizational scheme), the charge of both oxygens of the ester group of 
each compound (correlated), average charge of the triazole nitrogens (anti-correlated), and the 
total volume and substituent volume of each compound (anti-correlated). 
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Introduction 
Part 1: The Cannabinoid System 
 Marijuana, which contains the psychoactive cannabinoid ∆9-THC (∆9-
tetrahydrocannabinol), has been used for thousands of years for both its recreational effects and 
its medicinal benefits.1  It was not until 1964 that the compound was isolated and identified as 
the component responsible for the effects of cannabis by Gaoni and Mechoulam.2  At the time it 
was believed that ∆9-THC and it’s analogues produced their pharmacological actions through 
membrane disruption effects and not through ligand-receptor interactions.3   After high-affinity 
ligands were synthesized, making it easier to discover the associated target, the first cannabinoid 
receptor was discovered.4  It was termed cannabinoid type 1 receptor (CB1).  This established the 
ligand-receptor mechanism of cannabinoids’ actions.  Shortly thereafter the receptor was cloned, 
first in rats (1990), then in humans (1991).5,6  This led to the discovery of yet a second 
cannabinoid receptor (CB2) in 1993 by sequence homology analysis.7  Both of these receptors 
are A-Class (rhodopsin like) G-coupled-protein receptors (GPCR) and share their typical 
attributes.  The CB1 and CB2 receptors are concentrated in different areas throughout the body.  
The CB1 has been found primarily in the central nervous system in high concentration in the 
substantia nigra (largely responsible for the production of dopamine), globus pallidus, putamen, 
hippocampus, and cerebellum tissue.8,9  It is thought that this receptor subtype is primarily 
responsible for the psychoactive effects of cannabinoid ligands as the CB1 receptor is involved in 
memory, cognition, and the mediation of transmitter release through its coupling to ion channels 
in the brain.10  The CB2 receptor however is found primarily in peripheral tissues such as in the 
tonsils and spleen, adipose tissue, and throughout the immune system.11  The CB2 receptor is 
targeted by the drug industry primarily for therapeutic immune treatment as it is involved in 
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signal transduction in the immune system.12  The CB1 receptor, the receptor target of this study, 
however is targeted for a host of neuronal disorders such as obesity (in the case of overeating), 
nicotine and cocaine dependence, in the case of its antagonists, and stoke, multiple sclerosis, and 
Parkinson’s disease, in the case of its agoninsts.13,14  
 At the outset of drug development for the cannabinoid system there was very little 
knowledge of the endocannabinoid system.  Efforts were typically focused on modifying the 
structure of ∆9-THC, a tricyclic structured cannabinoid, in a manner that would inhibit the 
activation of the CB receptors without reducing its affinity for the receptor. This would 
effectively turn ∆9-THC, an agonist to CB receptors, into an antagonist.  These compounds are 
termed classical cannabinoids.  Though there are some good candidates from this research it has 
by enlarge been abandoned.15  In the early nineties while investigating non-steroidal anti-
inflammatory drugs, the company Sterling serendipitously discovered aminoalkylindole derived 
cannabinoid agonists. These drugs were related to the anti-inflammatory pravadoline.  The most 
notable of these drugs is WIN-55,212, which has a notably higher binding affinity than ∆9-
THC.16  These compounds were discovered to bind to a different region of the CB1 receptor than 
classical cannabinoids or anandamide (an endocannabinoid) which was verified by mutagenic 
studies.15,17  It has also been discovered that this region is the same region that binds rimonabant, 
which acts as a mild inverse agonist as opposed to an agonist.18  Other novel CB1 antagonists and 
inverse agonists have been discovered.  Azetidine (Aventis), Aryl-Imidazolidine-2,4-Dione 
(Didier Lamert team), Diarylimidazole (Merck), and 3,4-Diaryl-Pyrazolin (Solvay) derivatives 
have been reported to be antagonists or inverse agonists.19-22  None of these compounds have 
gained as much attention as rimonabant. 
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 In more recent years a large portion of the drug development effort has been directed 
towards creating drugs that have a similar scaffold to rimonabant (often referred to in the 
literature as SR141716A), including the compounds in this study.  Rimonabant was formerly 
prescribed in Europe for the treatment of obesity.  It is a lead compound of the diarylpyrazole 
derived class of cannabinoids introduced by Sanofi in 1994.13  Rimonabant is highly selective for 
the CB1 over the CB2 receptor, having a Ki value of 5.6 nM and over 1000 nM, respectively.  It 
is the first antagonist/inverse agonists to do so.  Evidence also suggests that rimonabant binds to 
other receptors potentially causing some of its in-vivo effects.23  Its intended goal of 
development was as an anti-obesity agent targeting CB1 receptors in the central nervous system 
to reduce food intake.24  It has been found that CB1 knockout mice are also leaner and resist diet-
induced obesity.25  This suggests that the mechanism includes more than just feeding behavior. It 
follows that if the activity of these receptors are blocked a similar result will occur.  In the 
United States over 100,000 deaths are estimated to be associated with obesity and its 
complications.  It is a major public health concern.26   
In the clinical study, Rimonabant in Obesity (RIO), a program conducted in various 
clinical centers globally, rimonabant was shown to be effective against placeboes in double blind 
trials in reducing different quantifiers of obesity.  In an overview of the research in 2008, which 
assessed cardiometabolic risk factors, Van Gaal27 sums up its findings.  Subjects in the study 
were given a placebo, 5 mg, or 20 mg of rimonabant daily.  They were also given a restricted 
calorie diet and an increased physical activity regime.  The side effects of the drug were analyzed 
using the Hospital Anxiety and Depression Scale to evaluate the psychological effects, if any, on 
the subjects.  It was found that for those taking a daily dose of 20 mg of rimonabant there was a 
reduction in weight by 6.3 kg to 6.6 kg versus a loss of 1.6 kg to 1.8 kg for those taking a 
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placebo over six months. Also an average of 3.6 cm of waist circumference reduction, 13.2% 
triglycerides reduction, 7.2% increase in HDL cholesterol, and a decrease in blood pressure were 
observed.27  Due to such positive initial results with the drug, despite having been taken off of 
the market for safety concerns, studies continue on rimonabant to assess tolerability.   
CB1 antagonists and inverse agonist, like rimonabant, have also shown promise in dealing 
with drug addiction.  It has been reported that ∆9-THC, a CB1 agonist, causes a “high” or a 
euphoric experience in humans and primates.  This is assumed to be the cause of the wide spread 
abuse of marijuana.28-31  The administration of rimonabant (90 mg) has been shown to reduce the 
effects of smoking marijuana without reducing ∆9-THC blood plasma concentration.  This 
suggests the effects are due to the blockade of the CB1 receptor, and not an alteration in the 
pharmacokinetics of ∆9-THC.32  Rimonabant has been shown to be effective in attenuating 
nicotine self-administration in rats and reduces the anxiety reducing effects of nicotine on mice 
that were pre-exposed to nicotine.33,34  There have been somewhat mixed results favoring 
rimonabant as an aid in the cessation of smoking in preclinical trials in humans under the 
program “Studies with Rimonabant and Tobacco Use” (STRATUS), with the STRATUS-US 
(United States) study showing a doubled rate of abstinence 42 weeks after a 10 week regime of 
20 mg of rimonabant compared to placebo.  The study also notes a reduction in weight of test 
subjects.35  CB1 agonists on the other hand, such as WIN 55,212-2, have been shown to increase 
nicotine self-administration.36  Rimonabant also has a positive effect on opiate self-
administration in rats and may have therapeutic usages in opiate addiction.37  Unfortunately 
studies on alcoholism are currently inconclusive.  Results from animal studies suggest a decline 
in self-administration.38,39  However, Human trials are too small and short in duration to be 
conclusive.40  Methamphetamine self-administration in rats is attenuated by rimonabant as 
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well.41  Although rimonabant has shown to be effective or partially effective in the treatment of 
the aforementioned substance addictions it has shown to be less effective in treating ongoing 
stimulant addictions.42-45     
 In spite of the beneficial therapeutic effects CB1 inverse agonists and antagonists have 
had in numerous studies, their potential as safe and effective drugs are not so clear cut.  
Rimonabant and other CB1 antagonist/inverse agonist treatment has side-effects and can 
adversely affect patients taking these drugs.  In the RIO studies of rimonabant, many adverse 
psychological effects of the drug were observed in substantial percentages, though they were 
generally mild.  These side effects usually occurred within the first few months of treatment.46  
They include psychiatric side effects such as anxiety, depression, irritability, and insomnia as 
well as physical side effects such as nausea, vomiting, and diarrhea.  In RIO studies twenty six 
percent of patients experienced psychiatric symptoms while only fourteen percent of patients 
receiving a placebo experienced psychiatric symptoms.  Nine percent was due to depression.47  
This is especially significant because people that are obese are already at a higher risk for 
depression.  The study excluded people with preexisting psychiatric disorders at the outset. Of 
the patients taking 20 mg doses, 13-16% discontinued treatment because of side effects.47-50   
 Due to adverse effects, rimonabant was withdrawn from the market and several other CB1 
receptor antagonist/inverse agonists were withdrawn from clinical studies in 2008 for similar 
reasons.  Other CB1 ligands include tatanabant (Merck), otenabant (Pfizer), ibipinabant 
(Solvay/Bistol-Myers Squibb), and surinabant (Sanofi-Aventis).51,52  With so many CB1 receptor 
antagonists/inverse agonists withdrawn from the market for psychiatric side effects, alternative 
approaches are beginning to be utilized: 
 
 
6 
 
1) Develop drugs that do not cross the blood brain barrier and rely entirely on 
peripheral effects to reduce weight. 
2) Select out patients that simple don’t respond adversely. 
3) Develop neutral antagonists instead of inverse agonists so that the drugs only 
competitively inhibit the CB1 receptor instead of deactivating it (In order for a 
CB1 antagonist to be effective in treating addictive disorders, the drug must 
cross the blood brain barrier). 
 
The first approach relies on the fact that a significant percent of side effects are due to 
direct interactions with the central nervous system (CNS) as previously noted. While CB1 
receptors have an effect on food intake when in the CNS, they also play a role in the hormonal 
signaling to the brain that food is required, causing the experience of hunger.  The experience of 
hunger is complex and involves interactions between adipocytes, the mesolimbic system, the 
hypothalamus and the gastrointestinal tract as well as the production of the hormones ghrelin and 
leptin.53  Along with the ability of the endocannabinoid system to regulate these interactions, it 
has also been shown in rat studies to increase adiponectin (when deactivated), an adipose tissue 
protein that increases fatty acid oxidation.54-56  This tactic focuses on the peripheral effects a CB1 
antagonist can have on the onset of hunger.  The second approach deals with the filtering out of 
potential patients based on their prior mental health and family history of mental health.  Some 
have suggested attempting to identify genes responsible for the depressive and anxiolytic 
symptoms, as it is known that CB1 receptors are present on both GABA and serotonin neurons, 
both of which are involved in anxiety and depression, and interact with the serotonin transporter, 
to select candidates for CB1 antagonist therapy.24,57-59  The third approach focuses on the idea 
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that the negative side effects of the compounds, as well as rimonabant, are due to these ligands 
being inverse agonists, and as such produce effects opposite of agonists (which are euphoric).  A 
neutral antagonist would, in theory, be able to block the receptor site without causing negative 
emotional side effects.  This would allow drugs that have both central activity (due to crossing 
the blood brain barrier), and peripheral activity, allowing for a greater variety of treatment uses.  
However there is debate as to whether this is possible in a system with endogenous ligands.60,61   
 Currently there are a host of drugs that target the endocannabinoid system that are offered 
on the market.  Nonselective cannabinoid receptor agonists are currently used as appetite 
stimulants, anti-emetics, tumor growth inhibitors, anti-glaucoma agents and for the treatment of 
multiple sclerosis.62-65  Synthetic ∆9-THC is currently sold as dronabinol.22  There are no CB1 
antagonists for the treatment of drug addiction or obesity.  And with the other drugs for obesity 
being suspended (dexfenfluramine, sibutramine), interest in CB1 antagonists has been rekindled 
despite past failings.57   
 The action of a CB1 ligand at the CB1 receptor depends on whether it is an agonist, 
antagonist, or inverse-agonist.  These three terms are all relative to the unperturbed equilibrium 
of active (R*) and inactive (R) states of the CB1 receptor.  That is to say, the CB1 receptor 
produces signal transduction in the absence of a ligand.  It has basal activity.  This activity is 
referred to as constitutive activity. This is explained using a hypothetical thermodynamic 
process.66  If binding of a ligand pushes the equilibrium in the direction of the active 
confirmation (R*), it is considered to be an agonist.   If it causes the equilibrium to favor the 
inactive confirmation (R), it is considered to be an inverse agonist.  If the ligand competitively 
binds but shows no efficacy, that is, it stabilizes both the active and inactive confirmations in a 
way that does not disrupt their natural ratio, it is termed an antagonist.  This model of a two state 
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system shared by all GPCRs is considered useful but rudimentary.67-69  It provides a template for 
understanding why inverse agonists produce the reverse effect of agonists (they reduce signal 
transduction) and why neutral antagonists are sought (they would inhibit both agonists and 
inverse agonists while not reducing basal signal transduction).  CB1 receptors follow the same 
receptor-ligand interactions as other GPCR.  The basic equation used to quantify their 
interactions is: 
     ·		  
where Ki is the value at which 50% of the receptor sites are binded to by a ligand. 
 and  are 
the unbound protein and ligand concentrations respectively.  Though the kinetics of 
 are the 
same as for agonist, inverse agonist, and antagonist as far as setting the 50% occupancy as Ki, 

 may represent an agonist-receptor complex, inverse agonist-receptor complex, or 
antagonist-receptor complex, in binding scheme. 
 Figure 1.1.1 illustrates the dynamic between Ki and efficacy in the cannabinoid system. 
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Figure 1.1.1:70 An illustration of the dynamic between inverse agonist, antagonist, and agonist with active (R*) and inactive (R) CB1 receptor 
confirmations is presented. 
 
Though the CB1 receptor does express signaling without ligand binding, there are two known 
lipid like ligands (agonist) that are endogenously produced.  These are called the 
endocannabinoids.  The two endocannabinoids to have been discovered are anandamide and 2-
arachidonoyl glycerol (2-AG).71-73  In in-vivo assays used to characterize the form of activity a 
ligand produces, agonist of the CB1 receptor induce analgesia, catalepsia, hypomotility, and 
hypothermia (in rats).74  Antagonist blockade the action of agonist.  And inverse-agonist produce 
effects opposite of those produce by agonist.  In in-vitro assays commonly cAMP quantification 
is used based on the cannabinoid receptors negative coupling to adenylyl cyclase.  A decrease in 
cAMP production is measurable with the administration of a CB1 agonist.  [35S]-GTPγS, due to a 
dual-coupling effect for the CB1 receptor, can also be used as an assay as it shares the 
commonality with the CB1 as among all GPCRs in that it binds to a GTP molecule when 
activated by an agonist.  So an agonist will increase the binding to [35S]-GTPγS, a radiolabelled 
analogue of GTP.75  This assay allows for the identification of full agonists, partial agonists, 
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neutral antagonist, and inverse agonist.  Based on these two assays rimonabant is considered to 
be a mild inverse agonist.76,77   
 Though the CB1 receptor has not been crystalized and no definite x-ray structure 
obtained, the potential binding site of CB1 agonist/inverse agonist has been explored 
computationally and experimentally by the use of homology and mutagenic studies.  3D 
homology models are frequently based on bovine rhodopsin, a GPCR, which has been 
structurally determined by x-ray crystallography at 2.8 Å resolution.   And the resulting 
predictions are tested by mutating specific amino acids in the presumed binding pocket to 
determine if binding has increased or decreased by the aforementioned bioassays.23,78,79  From 
these studies, specific amino acid residues have been identified as being directly involved in the 
binding of antagonist and inverse agonist to specific binding regions of the CB1 receptor.   
The CB1 receptor consists of seven hydrophobic alpha helix transmembrane segments 
(TMH), an intracellular C terminus, and a 116 residue long extracellular N terminus tail, which 
seems to have no relevance in receptor recognition.80  It consists of 472 total residues.70,81  There 
is evidence that not all CB1 ligands bind to the same receptor site.  Aminoalkylindoles, such as 
WIN 55,212-2, have been shown not to bind to the same location of the receptor as anandamide 
or classical cannabinoids (THC analogues), but bind to the same region as rimonabant.  This has 
been confirmed by mutation studies.17,18,82  This also points to the potential of there being 
multiple activation confirmations.  The binding site that has received the most attention is that of 
WIN 55,212-2 and rimonabant.  Figure 1.1.2 is an illustration of the hCB1. 
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Figure 1.1.2:78 A modeling based  CB1 receptor to the left (A) and the crystal structure determined rhodopsin (red) superimposed with the 
modeling based CB1 receptor on the right (B) are shown with the ligand binding region boxed in. 
 
 Several key areas of the receptor have been explored with modeling and mutation studies.  
K3.28 (Lys192) located in the third transmembrane domain (TMH3) of the human CB1 receptor 
(hCB1) was shown to be key in the inverse agonist action of rimonabant in mutation studies by 
substitution with K3.28A, the non-polar residue alanine.83  This was verified when molecular 
modeling techniques showed that the Lys192 residue interacts directly via hydrogen bonding 
with the C3 substituent (carbonyl group) of rimonabant.  This substitution does not stop 
rimonabant from binding to the mutant receptor as it will still antagonize WIN 55,212-2, but 
instead prevents it from acting as an inverse agonist/antagonist.84  When hydrogen bonding 
occurs between the Lys192 residue and the C3 substituent (carbonyl oxygen), a salt bridge with 
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D6.58 (Asp366) is stabilized.78  This stabilization of the Lys192-Asp366 salt bridge is thought to 
be responsible for inverse agonism/antagonism as it has been shown by modeling mutagenic 
studies to contribute to stabilizing the inactive state of the receptor (R).18  Studies of the binding 
domain at the CB1 receptor revealed that rimonabant binds within the TMH3-4-5-6 aromatic 
microdomain by aromatic stacking interactions with the F3.36 (Phe200), W6.48 (Try356), 
W5.43 (Try279), and the dichlorophenyl ring system of Rimonabant, and W4.64 (Trp255), 
Y5.39 (Tyr275), F5.42 (Phe278), and the monochlorophenyl ring system of Rimonabant.  Also, 
hydrophobic interactions occur between the piperidinyl moiety, V3.32 (Val196), F2.57 (Phe170), 
Leu387, and Met384.18,78,85  These studies also reconfirmed the Lys192 hydrogen bonding 
interactions with rimonabant.  WIN 55, 212-2 was shown to bind in the same domain but with 
aromatic stacking occurring with the Phe200, Try279, and Try356 residues.  It does not stabilize 
the Lys192-Asp366 salt bridge.  This causes it to acts as an agonist as it stabilizes the active 
confirmation.  Within this domain only the F3.25A (alanine) mutation had an effect on 
anandamide (which binds in the TMH2-3-6-7 region) binding, illustrating a separate binding 
location for anandamide from rimonabant.18   
 From these binding cues, rational drug designers can begin to make sense of binding 
affinity and efficacy data, and attempt to design drugs that mimic specific effects of a set of 
ligands based on their structure.  After key binding positions based on hydrogen bonding, sterics, 
electrostatics, and aromatic stacking (other properties may also be included) have been 
identified, a pharmacophore may be developed to represent a particular class of compounds, i.e. 
rimonabant-like inverse agonist.  Figures 1.1.386 and 1.1.485 are a basic illustration of a 
rimonabant-like inverse agonist pharmacophore (above), compared to rimonabant, and its 
presumed binding interactions within the CB1 receptor and a 3D pharmacophore. 
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Figure 1.1.3:86 A 3D pharmacophore mapped onto rimonabant:  A) Cyan spheres represent hydrophobic features.  B) Beige sphere represent 
aromatic features.  C) Green spheres represent hydrogen bonding features (small: hydrogen bond acceptor, large: hydrogen bond donor).  
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Figure 1.1.4:85 2D representations of the general pharmacophore’s (a) and rimonabant’s (b) interaction points with individual residues of the 
modeled CB1 receptor. 
 
The CB1 ligands in this study are rimonabant-like compounds and follow this basic 
pharmacophore model.  However they are triazole-centered, as opposed to pyrazole-centered 
compounds. They have been analyzed using high resolution x-ray crystallographic data, 
providing a more detailed look at their surface electrostatics (as binding is achieved by 
complementary surface properties), atomic basins, and bond ellipticities in an attempt to 
qualitatively correlate their affinity and efficacy to this data. 
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Part 2: High Resolution X-Ray Crystallography and the Electron Density Distribution 
 In principle, all of the physical and chemical properties of a molecule are the result of its 
distribution of electrons, the electron density distribution, ρ(r), and the distribution of nuclear 
charges.  From a knowledge of the electron density, it should be possible to obtain data useful for 
drug design such as atomic charges, molecular electrostatic potentials, and intermolecular 
interaction energies.87  This information can be gained in several fashions.  It can be computed 
theoretically using density functional theory or by a more traditional quantum mechanical 
approach (molecular orbital calculations), and empirically by direct measurement of the electron 
density via diffraction.  This study utilizes the direct measurement of the electron density 
distribution by high resolution x-ray diffraction intensity measurements at low temperature.  A 
high resolution description of the ED is necessary for an accurate determination of electrostatic 
moments as the features in the ED responsible for the above molecular properties occur due to 
slight alterations in the ED, caused by chemical bonding, at subatomic resolutions.87 
   In crystallography resolution can be quantified in terms of inverse angstroms (Å-1) as 
2sin(θ)/λ where λ is the wavelength of the x-ray radiation (0.71073 Å from a Molybdenum 
source, as used in this experimental setup) and θ is half the angle at which the x-rays diffract 
relative to the incident beam.  This formalism can be derived from the basic Bragg diffraction 
equation     .88  High resolution data is collected out to approximately 1.0 Å-1 or 
greater.  The use of this data not only allows for a better determination of positional and thermal 
displacement parameters associated with individual atoms in the molecule, but also yields a 
better deconvolution of the static electron density from the positional and thermal parameters.89  
In order to benefit from this, the static electron density must be modeled not on spherical 
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scattering factors, but on aspherical scattering factors.  This is what makes high resolution x-ray 
crystallography special in regards to a more accurate determination of the ED.  What follows is a 
basic description of this technique.87 
 The most fundamental equation in crystallography is: 
 ρr   1  
 !·" Equation 2.1 
where ρ(r) is the electron distribution within the unit cell, # is the reciprocatal volume of the unit 
cell,  is the structure factor, H is the scattering vector (in terms of h,k,l), r is the position vector 
in fractional coordinates (x,y,z) of the unit cell, and the   !·" are terms of the Fourier series 
expansion.  The volume of the unit cell can be determined by geometric analysis and will not be 
discussed here.  The determination of , where the differences in the conventional independent 
atom model (IAM) and high resolution x-ray crystallography are present, is more complicated.   
The structure factor, a complex variable, is mathematically represented by this equation: 
 
    $%&'%&!·"
(
%)
 Equation 2.2 
where '%& is the temperature factor of atom (j), a dynamic parameter, and $%& , a static 
parameter, is the scattering power of atom (j) at position (r) within the unit cell and in the 
direction of H, the scattering vector.  Both of these variables decrease with an increase in 
sin(θ)/λ.88  For anisotropic-harmonic temperature factors, the expression is as follows:   
  '%&    !*"+·,·"  
where U is the mean-square displacement amplitude matrix.  This equation is the result of the 
Fourier transform of the probability distribution function (pdf or P(u)) as a function of the 
nuclear displacement vector u) in the harmonic approximation of the nuclear displacement due to 
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vibration about the equilibrium position of atom (j) which follows a normal distribution.  Higher 
order treatments of thermal motion (anisotropic-anharmonic motion) may be treated with the 
Gram-Charlier expansion.90  The expression for aspherical scattering is: 
 $%&    - ρ% .!·"/. Equation 2.3 
where ρ%. is the electron density of atom (j) at position (r).  ρ%. is represented using the 
Hansen-Coppens formalism91:  
 
ρ%.   ρ0. 1 
2ρ23. 1 ρ34. Equation 2.4 
ρ0. is the core electron density expressed as a spherical function. ρ23. is the valence shell 
electron density (expressed by a spherical harmonic monopole), normalized to one electron, with 
an expansion-contraction parameter k that allows the monopole to scale in size.  
2 is the 
population parameter used to adjust the value of the monopole.  ρ34. is an expansion of 
spherical harmonic multipoles that takes into account aspherical valence shell electron 
deformations due to chemical bonding. It has its own expansion-contraction parameter 34.92  Its 
expression is: 
 ρ34r    5634
6
.  
67
6
7) 6
867 r. Equation 2.5 
The radial functions 56. are normalized Slater functions: 
 5634.   3
496:;
<= 1 2! .96 @
+"
 
Equation 2.6 
867 A" are normalized spherical harmonics that are multiplied by a population parameter in 
order to attenuate the amount of electron density relocated.  The ρ34. do not alter the total 
charge, as their integrals over all space are equal to zero.  They merely reallocate electron density 
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to another part of the atomic environment they describe.  All of these parameters are centered 
about the nucleus of the atom who’s ED they describe.91 
 Thermal parameters are more accurately determined using higher resolution data.  This is 
based on the principle that the core electrons are relatively unaffected by chemical bonding.  As 
a result, near the core of each atom there is a sharp peak in electron density that is relatively 
unaffected by bonding as in the case of valence electrons.  At high angle diffraction, or high 
resolution data B   C 0.75 Å I, the valence or bond density contribution to the Bragg 
reflections is greatly reduced due to limitations of the x-ray wavelength and electron density 
falling out of phase.89  Due to this phenomenon, it is approximated that all of the electron density 
contributing to the high angle Bragg reflections are from each atom’s core.  As core electrons 
occupy space near the nucleus and as mentioned earlier are not affected by chemical bonding, 
and therefore of spherical geometry, the nuclear probability distribution functions are refined 
using ED modeled on spherical scattering factors including this high resolution data.  In an 
attempt to limit the effect that temperature has on x-ray diffraction, as higher thermal parameters 
result in lower diffraction at higher angles and to ensure better signal to noise ratios at higher 
angles, data sets are collected on crystals that are cooled using a cryostream of nitrogen gas.  In 
this experimental setup data were collected at 120 K.  The result is better position and thermal 
parameters due to lower temperatures increasing the angle which x-ray intensities may be 
observed, and thus the inclusion of data at higher angles in the least-squares refinement. 
 As the actual data collected, || (observed as the intensity of reflection H), contains 
information on both the static scattering factor and the dynamic temperature factor, the two must 
be separated in order to obtain the static ED.93  This process is called deconvolution and relies on 
the Fourier convolution theorem which states that the Fourier transform of a convolution is the 
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product of the Fourier transforms of the individual functions KLM$ N OP   LM$P · LMOPQ.94   As 
the dynamic electron density of an atom is a convolution of static electron density with the 
probability density function [ρ%.   ρ%.RSTS0 N 
U] and the scattering factor is the Fourier 
transform of the static electron density $%&    V ρ% .!·"/. or $%&    LWρ%.X and 
the temperature factor is the Fourier transform of the probability distribution, '%&  
 V 
U!·"du or '%&    LM
UP, then the Fourier transform of the convolution of 
ρ%.RSTS0 with 
U is the dynamic scattering factor which includes both the static aspherical 
scattering factor and the temperature factors.  That is: 
 LWρ%. N 
UX   LWρ%.X · LM
UP = $%& · '%& Equation 2.7 
Once refined and deconvoluted the thermal parameters are subjected to a Hirshfeld test95 to 
ensure their reasonability.  In the Hirshfeld test, the mean square amplitudes of displacement due 
to thermal motion for bonded atoms are compared along the bond direction.   
 Accurate determination of  '%& from refinement of high resolution data at low 
temperature and  $%& with the use of the Hansen-Coppens formalism for asymmetric scattering 
factors, which introduces more refinable parameters, ultimately leads to a better model of the 
ED.91  The model parameters are refined using a least-squares method where the difference 
between observed and calculated structure factors is minimized by setting the derivative of the 
difference equal to 0, 
 
0    YM|Z| [ 3|0|P \|30|] %^  Equation 2.8 
where |Z| and |0| are the magnitudes of the observed and calculated structure factors 
respectively.  Here k is a scale factor used to bring the observed structure factors to the same 
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scale as the calculated structure factors.  The validity of the model may be tested by computing 
an R-factor which is the fraction of disagreement between |Z| and |0| in terms of |Z|, 
 5   _∑a|Z| [ |0|a∑|Z| b Equation 2.9 
Major improvements are noticed in this value after refinement with aspherical scattering factors 
compared to independent atom model (IAM), a rudimentary refinement in which scattering 
factors are approximated by spherical functions.93  It can also be visualized in order to assess the 
fit of the aspherical scattering factors to individual atoms or group of atoms using a Fourier 
difference map.  This is called the residual density. 
 ∆ρ"dR  e1fg |Z| [ |0|
hi !·" Equation 2.10 
Since the phase factor j cannot be measured experimentally, both the observed and calculated 
structure factors use the calculated phase information.  This is referred to as the model biasing 
problem as the model is biased towards the calculated phases.88  In Figure 1.2.1 the 
improvements to the fit of the model for one of the aromatic rings in the compound AVG-229Ph 
can be seen due to the employment of aspherical scattering factors and high resolution x-ray 
crystallography (left) compared to the fit with a spherical atom model (right). 
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Figure 1.2.1: An illustration of the difference density with spherical scattering factors (right) and aspherical scattering factors (left).  The lower R-
factor and lower peaks in the residual density map indicate a substantial improvement in the aspherical model compared to the spherical IAM 
model for the ED.  Contours are in 0.1  · Å ; increments.  Blue solid lines are positive increments. Grey dashed lines are negative. Dotted red 
lines hold a value of zero. To the left is a residual map in the plane of C(10), C(12), and C(14), part of a ring system in AVG-229Ph, at an 
approximate resolution of sin(θ)/λ =  1.1 Å .  The final refinement on F of the complete structure is R1 = 0.0248. To the right is the same ring 
system refined with spherical scattering factors.  The final refinement on F of the complete structure is R1 = 0.0462.   
 
 When a difference density is calculated by subtracting the density corresponding to 
neutral spherical atoms from the electron density of the crystal, is is called an electron 
deformation density (EDD), because it reveals how atoms are deformed due to chemical bonding 
and their crystal environment. 
 ∆ρ(r)EDD = ρ(r)multi -  ρ(r)promolecule Equation 2.11 
If ρ%.0"kRST6 is calculated by Fourier transformation of the experimental structure factors, Z, 
the deformation density is called an ‘experimental dynamic deformation density’ (as seen in the 
right side of Figure 1.2.1).  This density will include the smearing due to thermal motion of the 
atoms, and will suffer from noise due to errors in the x-ray intensity measurements and series 
termination errors due to the finite resolution of the experiment. 
 If, however, ρ%.0"kRST6 is calculated by direct evaluation of the multipole functions 
used in the Hansen-Coppens multipole model refinement,91 then the resulting difference density 
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is called the ‘model electron deformation density’, and can be either a ‘dynamic’ density if the 
thermal motion is included, or a ‘static’ density if the thermal motion is omitted from the 
calculation.96,97  Below is the (static) deformation density of the same ring system as in Figure 
1.2.2. 
 
Figure 1.2.2: Deformation density map of the same ring system in displayed in Figure 1.2.1.  Contours are in 0.1  · Å ; increments.  Blue solid 
lines are positive increments. Grey dashed lines are negative. Dotted red lines hold a value of zero. 
 
It is clear that electron density has moved into regions between atoms to create chemical bonds.  
This density may be analyzed to determine any one electron property such as atomic charge, 
bond order, and aromatic bonding character (ellipticity).  Once all qualifying measures of the 
model’s fit to the data have been checked and reviewed for error and “chemical sense” (if the 
results seem chemically reasonable), the molecular properties and moments of interest that are 
available to be calculated may be derived.87  
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Part 3: Useful Molecular Properties Determined From the Electron Density Distribution 
 For drug design, the principle molecular properties of interest include the electrostatic 
potential, ., net atomic charges, lm, and magnitude and ellipticity of the density in the 
bonding region between atoms.98  π-stacking is considered to be a major interaction with the CB1 
receptor binding site of the ligands tested.  Each property of an individual molecule is derived 
from the total electronic distribution and quantitatively analyzed relative to the rest of the 
molecule set in an attempt to correlate molecular features with pharmacological affinity in (Ki).  
Atomic charges are calculated by integrating the atomic basins of each nuclei in accord with 
Bader’s quantum theory of atoms in molecules (QTAIM).99 
A. Atomic Charges and QTAIM 
 The assignment of net charges has a long history in chemistry, and has proven to be a 
useful method of prediction of electrostatic interactions between molecules.  Atomic charge is 
also an indicator of an atom’s capacity for hydrogen bonding.  For instance if an oxygen or 
nitrogen is highly negative, it may act as a hydrogen bond acceptor.  If in the right orientation, 
hydrogen bonds will contribute to the stabilizing of the ligand-receptor complex.  In addition to 
molecular shape, a complimentary distribution of atomic charges may stabilize the complex 
through electrostatic interactions.100 This gain in stability may also be true of other 
supramolecular interactions that rely on similar mechanisms.   For this reason atomic charges are 
tabulated and analyzed.  In order to compute the atomic charges of an atom in a molecule, one 
must partition the molecular density among the atoms of the molecule.  In most schemes for 
obtaining atomic charges the partitioning is arbitrary.   
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 In QTAIM, defining where one atom ends and where another begins in a molecule is not 
arbitrary.  In order to properly understand the concept of an atom in a molecule, we must first 
provide a basic background on QTAIM topological analysis of the electron density.  This is not a 
comprehensive review of the topic and is only intended to provide a meaningful understanding of 
atomic basins and their charges.   
 Most attempts to obtain atomic charges and understand chemical bonding have been 
based on molecular wavefunctions which are solutions to Schrödinger’s equation.99  Although 
widely used, these methods are highly dependent on the approximations used, such as basis set 
size, and suffer from the arbitrary nature of the partitioning method.  Schrödinger himself warned 
against attaching physical significance to wavefunctions.101  However, the properties of 
chemistry and physics are based on phenomenon in real space.  QTAIM was developed as a real 
space description of the charge density distributions.  Its topological features serve as the carrier 
of physical information regarding the concepts of atoms, bonds, structure, and structural stability. 
Topological features of n. are associated with “critical points” (cp’s), locations in the 
electron density where the first derivative of n. is equal to zero (on.0  0.  They are 
defined by the behavior of the ED surrounding them.  The second derivative matrix, the Hessian 
matrix, of n. determines whether a cp is of a topology of (3,-3) [local maximum at .0 typically 
at a nuclear attractor], (3,-1) [local maximum at .0 in the plane defined by two axes and a 
minimum in the third, typically at the center of a bond], (3,+1) [local minimum at .0 in two axes 
and a maximum in the third, typically occurs at the interior of a ring system], or (3,+3) [ local 
minimum at .0 typically at the interior of a cage system].  When taking the gradient field vector 
(gradient path) starting from an arbitrary point and stepwise progressing to on.0  0, all paths 
terminate at one of the cps, a nuclear attractor, a bonding cp, or ring cp.  The nuclei serve as 
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attractors to ED, which makes sense.  A ridge line of density connects bonded atoms, with a (3,-
1) cp at the minimum (saddle point) along the ridge.  Topologically an interatomic surface can be 
defined as the set of trajectories that terminate at a (3,-1) cp.  This results in a partitioning of the 
ED in a molecule into individual point attractors centered at “atoms in the molecule” and the 
surrounding “atomic basin”.  Where one atomic partition ends and the other begins is considered 
an interatomic surface (pqr) of each respective domain.  It can be very elegantly expressed as: 
 on. · s.   0 for each point on the surface S(r) Equation 3.1 
where s. is the unit vector normal to the surface being evaluated at r.  This is called the zero-
flux surface and it defines the atomic basin, and contains the nucleus and volume of the electron 
density associated with it.  From this definition of an atom in a molecule, the atomic charge can 
be determined by taking the integral of the difference between the nuclear and electronic charges 
over the atomic basin within the zero-flux surface.  
 lm   tu [  vm Equation 3.2 
tu is the electronic charge and vm is the nuclear charge. The result is a definition of atomic 
charge and atomic volume based only on the electron density distribution which is independent 
of the basis set, or the method used for obtaining the density.  Below is a graph of the path 
trajectories in the plane of ring system from Part: 2 of this intro to illustrate in 2D how these 
surfaces appear.99 
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Figure 1.3.1: A 2D plane of trajectory paths in red through a ring system in AVG-229Ph.  The blue dots are saddle points (3,-1).  And the green 
dot is a ring center point (3,+1).  Straight black lines represent chemical bonds.  Curved black lines show the surface of the atomic basin as it 
passes though the plane. 
 
B. The Electrostatic Potential and Binding 
 The electrostatic potential (ESP) is considered to be a molecular property which is highly 
predictive of noncovalent interactions.  This includes hydrogen bonding and interactions that 
occur at the “surface” of a molecule and thus is expected to play a major role in initial phases of 
ligand recognition by a receptor site.102  Therefore we consider the computation of the ESP at the 
molecular surface of these compounds to hold useful information about the activity of each 
molecule.  This is because a ligand’s surface will be attracted to its negative compliment within 
the receptor site causing it to approach and begin to orient.  Along with complementary surface 
attraction, it may also help in understanding lipophilic/hydrophobic interactions, as the more 
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neutral the ESP is at a molecule’s surface, the less polar it may appear to surrounding 
molecules.103  This is far from the only factor involved in ligand-receptor binding.  It does not 
include entropy factors such as changes in the degrees of freedom of both the ligand or of the 
surrounding environment.  It also does not account directly for changes in molecular 
conformation as the molecules are not rigid. But it is necessary at the outset of ligand 
recognition.104 
 Before calculating the ESP, the value of an isodensity surface must be determined.  This 
is done by calculation of the ED at a particular isodensity value.  It should also be taken into 
consideration the effects that a perturbing field, such as that induced by an approaching 
molecule, will have on the ESP at that density level.  The nearer the ESP is to the “inside” of a 
molecule, the greater the density and the less effected it is by outside forces.  The isodensity 
value commonly used as a molecular envelope in the experimental determination of ESP is 0.007 
 · Å ; (approximately 0.001 au in e/bohr3) as proposed separately by Bader, and Politzer and 
Murray.100,105  Other low values are valid.  At this isodensity surface, features such as the lone 
pairs and π electronic charge are still apparent.  Below is a visualization of a typical isodensity 
surface. 
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Figure 1.3.2: An example of an isodensity surface of AVG-229Ph at the value of 0.007  · Å ;. 
 
 If one has both the electron distribution and the charge and location of the nuclei in the 
molecule, calculating the ESP is relatively straight forward.  The ESP is calculated as: 
 .    tq|5q [ .| [  -
n.4/.4
|.4 [ .|  Equation 3.3 
tq is the atomic charge of atom A at the position of 5q. |5q [ .| is the distance from the nuclei 
to point r, which will be calculated on the isodensity surface.  And the integral is the electronic 
charge produced by the ED at a distance of |.4 [ .| to point .4.  The total integral of the ED is a 
positive value and is then subtracted from the sum of the effects of all tq to account for the 
negative charge of the electron.100  The data on which the ESP is based are obtained in the 
crystalline environment, and the forces between the individual molecules in the crystal are 
electrostatic and therefore are complimentary to each other.  Thus, this ESP calculation may be 
more representative of a ligand in solution or in the binding pocket than an ESP calculated from 
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wavefunctions for a molecule in a vacuum.104  The ESP is not to be calculated at every point, but 
only at points where n.   0.007  · Å ;.  The resulting ESP is the surface electrostatic 
potential and is denoted as R.106  When projected with a color gradient it may be analyzed 
visually to determine whether it is positive or negative as well as the strength of the potential.  In 
this fashion one may compare multiple molecules against one another and compare the ESP with 
other data such as each molecule’s affinity, to identify any regions whose ESP may play an 
important role in binding.  Figure 1.3.3 shows the ESP projected on to the molecular surface 
from Figure 1.3.2.  A similar type of analysis has been performed previously by Politzer and 
Murray on a series of compounds to assess the toxicity of ligands (dibenzo-p-dioxins) that bind 
to a porphine like receptor, the cytosolic receptor.  It was found in that study, and later verified 
by modeling studies, that two compounds exhibited very different toxicities due to an 
accumulation of or lack of negative ESP in the center ring system.  This feature of negative ESP 
in dibenzo-p-dioxin, centered around oxygen groups, prevented it from binding due to 
interactions with nitrogen lone pairs within the receptor site.  The added chloro-groups in 
2,3,7,8-tetrachlorodibenso-p-dioxin, which is structurally similar otherwise, provided enough 
electronegativity to prevent this accumulation of negative ESP on the oxygen groups of the 
molecule.  This change in ESP (observed in other compounds as well) increased binding to the 
receptor causing greater toxicity.  Other compounds similar in structure with the added chloro-
groups that were able to maintain the negative ESP showed reduced toxicity as well.100  Efforts 
to experimentally determine the affinity of compounds from experimental electron distributions 
has also been conducted by A. Pinkerton on estrogen molecules.104  
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Figure 1.3.3: The isodensity surface from Figure 1.3.2 with the ESP mapped on to the molecular envelope. 
 
 Though very local alterations in the ESP may change binding affinity, it is also 
recognized that more global parameters may be predictive of binding as well.100  This is because 
not all ligand-receptor binding occurs in the same fashion.  Some ligands-receptor interactions 
are due to broader contacts.  To asses this, it is possible to calculate several globally defined 
statistics of the ESP to analyze the general interaction properties functions (GIPF). These are 
properties introduced by Politzer and Murray.107,108  Of interest are the average deviation (w), 
total variance (xyzy), balance parameter (f), and maximum and minimum values of the ESP. 
 w  1< |R{ [ |R|
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 f  j: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xSZS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 Equation 3.6 
 
C. Bond Ellipticity as an Indicator of Aromaticity 
 Another property of the ED of interest is the bond ellipticity, as π-stacking is considered 
to be a significant factor in the binding of CB1 ligands.  x-bonds are cylindrically symmetric 
while π-bonds are elongated perpendicular to the molecular plane.  For single or double bonds, 
the amount of π character a bond has can be quantified by its ellipticity.  Single bonds display an 
ellipticity of close to zero while double bonds are near 0.2 among C-C interactions.109  In 
QTAIM, bond ellipticity is calculated as: 
     [ 1 Equation 3.7 
where  and  are the principle curvatures perpendicular to the bond path (the two negative 
eigenvalues of the Hessian matrix).   is the component that undergoes contraction (thus   < 
).  It will be analyzed to see if molecules with higher ellipticity in their aromatic ring systems 
have a greater affinity for receptor binding. 
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Methods 
Part 1: Crystallization 
 Each crystal in this study was obtained by slow solvent evaporation from a solution 
contained in a scintillation vial.  By covering the vial with parafilm with small needle sized holes 
poked in it, solvent was allowed to slowly evaporate at ambient temperature and pressure.  Many 
different solvents and mixed solvents with varying ratios of solvents were used until adequate 
resulting crystals were grown.  Frequently crystals took several weeks or months to form, if at 
all, as the compounds are prone to retain non-polar solvents.  Non-polar solvents generated the 
best results.  Compounds rarely dissolved in polar solvents.  And attempts to “crash” crystals out 
of solution via polar solvent dilution or by increasing the temperature to increase solubility, then 
reducing the temperature to bring the saturated solution beyond its saturation point, resulted in 
unsuitable crystals due to small size or disorder within the crystal on a molecular level.  
Diffusion methods were also explored but generally failed to generate usable crystals within the 
time invested.  After evaporation of solvent, the vials were examined under a stereoscopic 
microscope with light polarizing capabilities to determine if potential crystalline samples had 
formed.  Only crystals that appeared under polarized light to be single, non-twinned crystals 
without satellite crystals were considered as candidates for data collection.  If crystals were too 
large in any dimension to remain within the diameter of the x-ray beam during the experiment, a 
razor blade was used alter their shape.  This was frequently problematic as many compounds 
formed brittle crystals that shattered under the pressure of the blade.   Table 1 contains details on 
solvents used to obtain the crystals used for successful data collection, and the morphology of 
each crystal.  
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Compound Mol. Formula Solvent Crystal Dimensions (in mm) Morphology 
AVG-229Ph C21 N2 O2 Cl2 F1 H13 DCM 0.4 x 0.5 x 0.5 Block 
HS-P183 C17 N3 O2 Cl3 H12 1 THF : 1 EtOH 0.15 X 0.3 X 0.5 Plate 
HS-P226 C17 N3 O2 Cl3 H12 THF 0.5 X 0.5 X 0.6 Block 
HS-P53-1 C16 N3 O2 Cl2 H11 1 THF : 2 EtOH 0.17 x 0.2 x 0.4 Needle 
HS-P53-2 C14 N1 Cl2 H9 
1 THF : 1 EtOH : 1 
CHCl3 
0.1 x 0.5 x 0.5 
Plate 
HS-P57-2 C14 N3 Cl3 H8 CHCl3 0.25 x 0.5 x 0.6 Plate 
HS-P57-3 C17 N3 O2 Cl3 H12 1 THF : 1 Acetone 0.2 x 0.5 x 0.5 Plate 
HS-P57-4 C18 N3 O2 Cl3 H14 EtOH 0.25 x 0.5 x 0.5 Plate 
HS-P57-7 C21 N3 O2 Cl3 H18 1 THF : 3 Acetone 0.07 x 0.2 x 0.5 Needle 
HS-P69 C20 N5 O1 Cl3 H18 1 DCM : 3EtOAc 0.15 x 0.25 x 0.5 Plate 
Table 2.1.1: Basic compound and crystal information. 
 
Part 2: Crystal Mounting and Data Collection  
 Once crystals were grown, selected, and trimmed, they were glued to a glass needle under 
the microscope with an amorphous epoxy resin.  Each needle was then individually placed at the 
end of a goniometer head and fitted on to the goniometer of the x-ray diffractometer.  Each 
crystal was centered in the x-ray beam path and the cooling nozzle lowered into place.  After 
mounting, cooling to the final temperature, and centering the crystal, collecting data was begun.  
 Data were collected on a Bruker Kappa Apex II 4-circle diffractometer with each sample 
cooled to 120(2) K via a gaseous N2 stream generated by an Oxford Cryostream 700 low 
temperature device.  A Molybdenum target x-ray source and graphite monochromator was used 
producing x-rays with a wavelength of 0.71073 Å.110  An Apex II CCD detector was placed 
40.00 mm or 60.00 mm away from the sample, depending on the size of the unit cell.  
Compounds with larger unit cell dimensions were collected at 60.00 mm to avoid reflection 
overlap as larger direct space cell dimensions result in contracted reciprocal space cell 
dimensions, the space data is collected in.  The length of x-ray exposure per frame varied from 
20 to 300 seconds depending on the 2θ angle range being observed (higher angles require longer 
exposures), crystal size, and individual diffraction capacity of each compound.  The x-ray beam 
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was defined by a 0.6 mm collimator which limited the size of the uniform region of the x-ray 
beam, and thus the size of the crystal sample that could be used.  Scans were conducted varying 
either omega or phi angles with the other axes remaining fixed per scan. That is, for an omega 
scan over 115 degrees, phi, chi, and 2θ angles were set at fixed values while omega was varied.  
Each frame was collected over a 0.5 degree sweep for the 20 to 300 seconds allotted for that 
collection.  The number of reflections, redundancy, and peak resolution differed from compound 
to compound. The consistency/internal agreement of the data was verified against itself and 
quantified in R(int):88 
 R    | [ |  Equation 2.2 
Table 2.2.2 is a basic description of each data set after data processing. 
Compound Unique Reflections Avg. Redundancy Peak Resolution (Å) R(int) x 100 
AVG-229Ph 15,821 12.86 0.48 1.83 
HS-P183 18,220 6.37 0.45 2.28 
HS-P226 14,985 7.17 0.456 1.51 
HS-P53-1 11,923 8.74 0.5 2.41 
HS-P53-2 9,174 9.71 0.47 2.47 
HS-P57-2 10,494 8.24 0.47 2.24 
HS-P57-3 12,952 4.4 0.47 1.53 
HS-P57-4 42,192 15.7 0.55 2.53 
HS-P57-7 10,740 7.51 0.45 2.39 
HS-P69 15,848 9.43 0.52 2.00 
Table 2.2.2: An overview of crystal data quality. 
Part 3: Independent Atom Model Refinement Using Apex2/Shelx  
After data were collected for a crystal, they were was processed and refined using the 
Apex2/Shelx software package.111,112  Initially, a small set of reflections were indexed and used 
to determine the unit cell of each compound, and the Bravais lattice was determined using 
geometric analysis.  This unit cell was then used to predict the locations of all reflections to be 
integrated for total intensity.  The integration program “searches” for a reflection in the predicted 
location with an initial box around the reflection.  The box size is refined so that it includes the 
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entire reflection and subtracts out the background noise by measuring the intensity surrounding 
each reflection.  Reflections typically span several frames and it is the total intensity count across 
these frames that yield the integrated intensity value.  Also, using lower angle date, where the 
signal to noise ratio is higher, a reflection’s 3D profile is computed to help box size optimization 
and noise subtraction of weaker reflections and reflections that occur at greater 2θ values.  This 
is done because the signal to noise ratio at higher angles or higher resolution is much lower.  
During this process, cell dimensions are further refined using a larger set of reflections.  Once 
reflection intensities have been determined, the data are corrected for absorption in the 
subroutine Scale, formerly known as SADABS.113  This corrects for absorption of x-rays that 
have to pass through a greater or lesser distance through the crystal, as the crystals are not 
spherical.  This is done by comparing differences in multiple measurements of the intensities that 
should be equivalent due to Friedel’s Law or symmetry.114,115  The shape of the crystal’s 
absorption correction surface is defined by refining coefficients of a spherical harmonic 
expansion, which is used to calculate corrections for the remaining reflections.  From this, each 
reflection’s intensity is adjusted for absorption.  The corrected file of intensities is analyzed 
using Xprep.112  Xprep determines the space group of a crystal by looking for systematic absences 
or “holes” in an x-ray pattern that are caused by the presence of specific symmetry elements.  
Along with the Bravais lattice, this information is used to assign a space group may.  Xprep 
outputs an intensity data file (.hkl) for Shelx which is used to refine the parameters based on the 
independent atom model (IAM).96,111.  Also, for future use in the refinement strategy, a merged 
HKL file is generated for use by the program XD2006116 in which all duplicate data is averaged 
with the data spread present as a standard deviation for each observation.  Structure solution was 
performed by direct methods within Shelx.  Initial phasing using the direct methods solution with 
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the best figure of merit was used to calculate an approximate electron density (e-map).  The XP 
module with Shelx was used to assign atoms to peaks in the electron density, referred to as Q-
peaks, which also assigns the spherical scattering factor associated with that atom in the position 
of the Q-peak.  These are tabulated within Shelx.  XP produces an instructions file (.ins).  This 
file, with its new scattering factors, in turn was used to refine thermal parameters and atomic 
positions via least squares with the XL module.  XL produces a results file (.res) that was used 
by XP for further manipulation of atom assignment.  This process of refining positional and 
thermal parameters with least squares in XL (which also generates new Q-peaks) and assigning 
atoms was performed repeatedly until no further improvements could be made.  On all occasions 
for the final data sets used in the study, after adding anisotropic thermal parameters, and peaks 
corresponding to hydrogen atoms were clearly present in the difference map generated by XL, 
and hydrogen atoms were added to the least squares refinement model.  All final data sets were 
absent of disorder and had reasonable thermal parameters, a prerequisite for high resolution 
analysis of the ED.  Once satisfactory results were achieved at this stage, the resulting .ins file 
and merged .hkl file were exported to XD2006 for further refinement.116  Varying R-factors were 
recorded for each compound and are tabulated in the results section. 
 
Part 4: XD2006 and the Hansen-Coppens Formalism with Aspherical Scattering Factors 
The computer program XD2006 was used for the refinement of high resolution data with 
aspherical scattering factors using the Hansen-Coppens multipole formalism.91,116  The Windows 
interface for XD2006 is shown in Figure 2.4.1 where graphics are displayed and text 
notifications of refinements in process appear.  In this case a simple stick model of AVG-229Ph 
is displayed.   
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Figure 2.4.1: XD2006 interface screen. 
 
Once a refinement has been completed in APEX2112 and the instructions and HKL files copied to 
a working directory in the XD2006 file system, the XDINI module is executed.  This produces 
files usable to XD2006, namely the input file (.inp), a XD2006 compatible HKL file, and a 
master file (.mas).  The input file is where the parameters (temperature parameters, positions, 
multipoles, kappa values) of the molecule are written.  This file is ultimately the description of 
the electron density of the asymmetric unit and is used to calculate all properties derived from it 
by all modules with XD2006.  The HKL file is relatively unaltered and contains the intensities 
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and standard deviations of each reflection.  The master file contains all basic information about 
the cell (dimensions, symmetry operations, etc.) and instructions for each individual module.  
The primary modules of XD2006 involved in this study are XDLSM, XDFOUR, XDPROP and 
TOPXD.  To illustrate how a refinement is performed in XD2006 and how these modules are 
utilized, the refinement of AVG-229Ph will be detailed.  All other compounds are refined in the 
same basic fashion. 
 After usable files for XD2006 have been created, a local coordinate system must be 
assigned to each atom in the asymmetric unit.  This must be done keeping in mind the shape of 
spherical harmonic functions that will be used to refine the ED and their orientation to each axis.  
Shown below is a segment of the XDLSM module portion of the master file which contains a list 
of atoms in the first column (ATOM) that corresponds to the molecule in the graphical display 
above.  This is the atom for which the local coordinate system will be centered.  In the second 
column (ATOM0) is the atom whose position will serve as the direction of a vector for which an 
axis will be assigned.  This axis assignment is in the third column (AX1).  The fourth (ATOM1), 
fifth (ATOM2), and sixth (AX2) columns function in the same fashion except that the only the 
components perpendicular to the previous vector are used.  This resulting vector is also centered 
at the atom in the first column.  The third axis (the only unlabeled axis left) is generated normal 
to the plane defined by the first two vectors.  The seventh column (R/L) defines the handedness 
of the axis system and therefore the direction of the remaining axis.  This means that for local 
coordinates of O(2), the vector from O(2) to C(7) is defined as the x-axis.  The component of the 
vector from C(8) to O(1) that is perpendicular to the previous axis is defined as the y-axis.  And 
the normal vector to the resulting plane is the z-axis in the direction that creates a right handed 
axis system.   
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Figure 2.4.2:  Atom list, local coordinate setup, chemical constraint, and refinement options layout of an XD2006 master file. 
 
Also present in this section is the level of treatment for thermal parameters designated in column 
8 (TP).  A value of 1 designates the use of isotropic thermal parameters (scalar), 2 designates 
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anisotropic harmonic thermal parameters, and 3 and 4 designate anisotropic-anharmonic thermal 
parameters.  In most cases anisotropic-harmonic thermal parameters are sufficient.  But in this 
model Cl(1) refined better with anharmonic anisotropic thermal parameters.117,118  This was 
evident in an improvement in the residual map of both atoms.  Column 9 (TBL) defines which 
core and valence scattering factor tables are used for each atom.  Column 10 (KAP) specifies 
which set of kappa values will be refined with that particular atom.  Several atoms that are of a 
similar environment will usually use the same kappa set.  When XDLSM performs a least 
squares refinement on a set of kappas it considers all atoms associated with that set.  Column 11 
(LMX) designates the level of the spherical harmonic multipoles whose populations may be 
refined for that atom.91  Designations of these spherical harmonics are as follows: 0–monopole, 
1–dipole, 2–quadrapole, 3–octapole, and 4–hexadecapole.  If 2 is selected as in the case of the 
hydrogen atoms monopole, dipole, and quadrapole spherical harmonic functions may be used to 
refine the atoms ED but not octapole and hexadecapole functions.  All other atoms in this study 
that are not hydrogen use up to the hexadecapolar level of refinement.  Column 12 (SITESYM) 
was not used for any compounds as no atoms were located on special symmetry sites.  The last 
column (CHEMCON) is used to apply chemical constraints to the multipole parameters of the 
atom in that row to be identical to those of the labeled atom.  In this case Cl(2)’s multipoles are 
constrained to be the same as Cl(1)’s.  The least-squares process is modified so that the resulting 
parameters are those that provide the best overall fit at both atoms.119  Typically all aliphatic 
hydrogens are constrained to be equal as well as all aromatic hydrogens.  The benefit of these 
constraints is that there is a reduction in the number of refined parameters.  For the optimization 
problem to be over determined, for every parameter to be refined there must be more than one 
experimental observation, a reflection.  The more reflection there are per parameter, the more 
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over determined the system is.  In analysis of x-ray data, over determination by a factor of 10 
observations per parameter is considered desirable.  Since the number of observable reflections is 
often limited by the details of the experiment, the model should be as efficient as possible by 
reducing the number of parameters as much as possible. 
 With local coordinates set up for each atom, expansion contraction parameters92 (kappa 
values) are assigned, and the multipoles of chemically independent atoms are selected to be 
refined. 
 
Figure 2.4.3.: Example of thermal parameter and multipole refinement setup within the master file LSM module in XD2006. 
 
Shown above is a list of parameters to be refined for the first 10 atoms in AVG-229Ph for 
illustration.  All of the digits in this caption are potential parameters to refine (0 – do not refine, 1 
– refine).  After the atom names the next there columns are position parameters.  These are 
refined on every least squares cycle except for hydrogens.  The following three sets of columns 
(U2, U3, and U4) define what level of thermal motions refinement will be used.  Typically U2 
(anisotropic-harmonic) is refined for all atoms except for hydrogens.  In this case Cl(1) refined 
better with anisotropic-anharmonic thermal parameters.  As seen for these atoms, the entire 
column U3 has ‘1’ designations for these parameters.  All of the anharmonic parameters are 
refined based on the Gram-Charlier temperature factor formalism.90  The multipole section 
works differently.  Each digit stands for a different multipole deformation parameter.  In column 
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-D- there are three digits.  The first dipole is anti-symmetric about the x-axis (negative in the 
negative range of x and positive in the positive range of x), the second about the y-axis, and the 
third about the z-axis.  But each is also symmetric in the other two unmentioned axes.  All of the 
multipoles are either symmetric or anti-symmetric about a particular axis or axes.  When setting 
up the local coordinates, the symmetry of the local environment was taken into account to exploit 
these symmetry properties of the spherical harmonics functions.119  This attention to symmetry 
allows for a further reduction in the number of refined parameters.  As is shown in Figure 2.4.3, 
Cl(1) only has one dipole being refined, the dipole anti-symmetric about the z-axis.  This is 
because its z-axis is aligned along the bond path, and it is expected that electron density from 
Cl(1) will be moved into the bonding region.  As electron density in the Cl-C bonds is expected 
to be cylindrically symmetric, the populations of the x-dipoles and y-dipoles are not refined, but 
are fixed at zero.  This same logic is applied to the remaining spherical harmonic multipoles.  
This is done for every single independently refined atom in the asymmetric unit.  Figure 2.4.4 
shows the spherical harmonics with a radial function applied up to the octapolar level. 
 
 
Figure 2.4.4: Examples of spherical harmonic functions. 
 
 
 
43 
 
 During a multipole refinement, all of the potential multipole populations may not be 
refined at once.  Usually the monopole populations are refined first.  Next monopole and 
octapole populations are refined.  Then monopole, octapole, and quadrapole populations are 
refined.  And finally all potential multipole populations are refined at once.  The monopole 
kappa is refined at every step of this refinement process as well.  This strategy is followed 
because there is a correlation between the multipole populations.  The multipoles that are 
typically the most populated are refined first.  Once the monopole kappa and multipole for every 
atom has been refined to convergence, the monopole kappa and the kappa for the multipoles 
(which are constrained to be equal across all multipole kappas per kappa set) is refined.  Then it 
is cycled back through the monopole kappas and multipole population refinement again.  These 
two refinements are cycled till convergence.  Once converged and the R(F) has reached its 
minimum, the modeling of the ED has been completed.  Residual maps generated by difference 
Fourier transforms within the XDLSM module are then produced.  Using the XDFOUR module 
these maps are plotted and analyzed for quality.  The less residual density, or unmodeled density, 
the better the refinement is.  Once satisfied with the refinement, molecular properties based on 
the ED and nuclear positions may be derived.  This is performed by the XDPROP and TOPXD 
modules.116  Properties that were computed are the ESP, bond critical points, and bond ellipticity 
using XDPROP, and atomic charges using TOPXD.  The ESPs were projected onto the ED at a 
density isosurface value of 0.007  · Å ; using the computer program MolIso.120  
 
Part 5: Data Analysis and Principal Component Analysis 
 All data analysis was conducted using R (programing language) within RStudio 
(integrated development environment).121,122  Before a covariance matrix was generated, to 
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determine correlation, each data set was mean centered by subtracting the mean of each property 
from each value and scaled by dividing by that set’s standard deviation to account for unit 
variance.  The covariance matrix of each property with Ki was solved. This entire process was 
repeated three more consecutive times, each time leaving out the most extreme data point.   
Correlation was then determined by observing which variables maintained correlation with Ki 
throughout all covariance matrices.  Principal component analysis123,124 was performed only on 
the correlated parameters.  This was performed by singular value decomposition.125  The data 
was projected onto the first three principal components (PC) using the ‘rgl’, ‘scatterplot3D’, and 
‘BPCA’ packages for R.126-128   For the purpose of this document to substitute for a three 
dimensional rendering of the data, two biplots were provided of the data projected onto the first 
and second principal components, and the second and third principal components.   
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Results 
 
 This section contains data on ten separate molecules provided by Professor Mark Trudell, and 
his collaborators Dr. Hong Shu, and Dr. Aba Verma of the University of New Orleans.  Each molecule has 
been structurally determined via high resolution x-ray crystallography at low temperature (120 K).  A 
charge density study using the Hansen-Coppens multipole formalism91 has been conducted on each 
molecule to generate atomic position and thermal parameters as well as the charge/electron 
distribution.  ORTEP129 (Oakridge thermal ellipsoid plot) diagrams at 50% occupancy are presented.  An 
analysis of the electronic distribution of n. has yielded the topological parameters n
 (charge 
density at the bond critical point), n
 (Laplacian of the charge density at the bond critical point), 
 (bond ellipticity), lm (charge of the atomic basin), and m (volume of the atomic basin).  
Furthermore, an ESP (electrostatic potential) map has been graphed on to an isodensity surface (at a 
value of n.   0.007  · Å ;) for each molecule. 
 The molecules have been arranged by decreasing Ki (affinity).  Relevant information about the 
molecule, crystal system, and x-ray data has been tabulated for each molecule.  Experimental details 
considered important or unusual have been brought to attention.  Finally a table of Politzer’s and 
Murray’s global parameter analysis100 of the ESP is given.  A discussion of these results follows. 
Note: All Ki values produced by Professor Sari Izenwasser, Department of Psychiatry and Behavioral 
Science, University of Miami, Miller School of Medicine. 
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Compound 1 
Name: 
HS-P53-2  
1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole 
Affinity:  
Ki = 6,931 nM ± 1305 
ORTEP: 
 
Figure 3.1.1 
 
ESP Maps: 
 
 
47 
 
 
Figure 3.1.2 
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Figure 3.1.3 
 
Refinement Note: 
A broad peak shows a maximum at 3 contours (0.30  · Å ;) about Cl(2) in the plane of C(9), C(11), and 
C(13).  All other residuals are relatively flat.  The R(F) value of the overall refinement is low. 
Crystal Data Table: 
General Sample Information 
Molecular formula C14 N3 Cl2 H9 
Formula weight 289.02 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Monoclinic P 
Space Group Pc 
Cell Dimensions   
a (Å) 5.9897 
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b (Å) 14.1988 
c (Å) 7.8827 j 90.000  106.598  90.000 
Volume 642.46 
Density 1.500 Mg/m3 
Absorption coefficient 0.492 mm-1 
Crystal size (mm) 0.1 x 0.5 x 0.5 
(sinθ/λ)max (Å-1) 1.04 
Unique reflections 9,174 [R(int) = 0.0247] 
Average redundancy 9.71 
Completeness to (sinθ/λ)max 88.0% 
Absorption correction Empirical (tmin = 0.756, tmax = 0.952) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters 8709 / 2 / 208 
Goodness-or-fit on F2 1.079 
Final R indices [I>2xI R1 = 0.0286 
R indices (all data) R1 = 0.0310, wR2 = 0.0752 
Largest difference peak and trough 0.719 and -0.216  · Å ; 
Nref/Nv 41.87 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 4791 / 0 / 416 
Goodness-or-fit (GoF) on F 2.580 
Final R indices [I>2xI R1 = 0.0184, wRF = 0.0175 
R indices (all data) R1 = 0.0247 
Largest difference peak and trough 0.409 and -0.296  · Å ; 
Nref/Nv 11.5446 
                           Table 3.1.1 
5   ∑ a|| |i|a|| ; Y5   B∑ || |i|
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.6860E+01 1.3928E-01 26.8831 
Cl(2) 1.6987E+01 1.2069E-02 27.2336 
N(1) 7.6034E+00 -6.0341E-01 14.7759 
N(2) 7.3178E+00 -3.1781E-01 13.4547 
N(3) 7.7570E+00 -7.5706E-01 10.1103 
C(1) 6.1300E+00 -1.3008E-01 11.3531 
C(2) 6.1964E+00 -1.9646E-01 12.0251 
C(3) 5.9918E+00 8.1960E-03 9.9707 
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C(4) 6.1860E+00 -1.8603E-01 11.2965 
C(5) 6.1341E+00 -1.3417E-01 10.7558 
C(6) 6.0951E+00 -9.5100E-02 10.2236 
C(7) 5.7426E+00 2.5735E-01 9.1335 
C(8) 5.6961E+00 3.0387E-01 10.6910 
C(9) 5.7993E+00 2.0068E-01 8.5368 
C(10) 6.0558E+00 -5.5830E-02 11.5950 
C(11) 6.1080E+00 -1.0808E-01 12.6186 
C(12) 6.1292E+00 -1.2929E-01 10.4751 
C(13) 6.1038E+00 -1.0384E-01 12.3981 
C(14) 6.0500E+00 -5.0035E-02 11.3086 
H(1) 9.1174E-01 8.8259E-02 5.8863 
H(2) 8.9381E-01 1.0618E-01 5.7417 
H(4) 9.0072E-01 9.92790E-02 5.9974 
H(5) 9.0207E-01 9.7924E-02 5.9171 
H(8) 9.4970E-01 5.0291E-02 6.0423 
H(10) 9.1805E-01 8.1946E-02 6.5716 
H(11) 8.9279E-01 1.0720E-01 6.0461 
H(13) 8.9961E-01 1.0038E-01 6.2949 
H(14) 9.2851E-01 7.1488E-02 6.0058 
           Table 3.1.2 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Monochlorophenyl Ring [N(3) 
connectivity] 
 
Inner Carbon Bonds     
 C(9)  -  C(10) 0.07 2.341 -21.963 
C(10)  -  C(11) 0.04 2.200 -18.077 
C(11)  -  C(12) 0.01 2.337 -21.525 
C(12)  -  C(13) 0.00 2.351 -21.838 
C(13)  -  C(14) 0.04 2.222 -18.645 
C(14)  -  C(9) 0.06 2.342 -21.943 
Outer Atom – Inner Carbon Bonds     
 N(3)  -  C(9) 0.10 1.985 -12.708 
H(10)  -  C(10) 0.02 1.912 -20.330 
H(11)  -  C(11) 0.03 1.867 -19.299 
Cl(2)  -  C(12) 0.04 1.547 -3.642 
H(13)  -  C(13) 0.03 1.872 -19.421 
H(14)  -  C(14) 0.02 1.911 -20.286 
Monochlorophenyl Ring [C(7) 
connectivity] 
 
 Inner Carbon Bonds     
 C(6)  -  C(1) 0.21 2.110 -17.137 
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C(1)  -  C(2) 0.25 2.071 -13.765 
C(2)  -  C(3) 0.42 2.295 -21.845 
C(3)  -  C(4) 0.32 2.222 -18.616 
C(4)  -  C(5) 0.25 2.072 -13.803 
C(5)  -  C(6) 0.21 2.109 -17.073 
Outer Atom – Inner Carbon Bonds     
 C(7)  -  C(6) 0.08 1.829 -12.607 
H(1)  -  C(1) 0.20 1.896 -19.603 
H(2)  -  C(2) 0.02 1.911 -18.953 
Cl(1)  -  C(3) 0.12 1.226 -2.307 
H(4)  -  C(4) 0.02 1.907 -18.833 
H(5)  -  C(5) 0.20 1.886 -19.328 
Triazole Ring   
Inner Atom Bonds     
 N(1)  -  N(2) 0.02 3.025 -12.858 
N(2)  -  N(3) 0.29 2.508 -7.922 
N(3)  -  C(7) 0.22 2.197 -20.672 
C(7)  -  C(8) 0.16 2.318 -24.945 
C(8)  -  N(1) 0.24 2.105 -14.703 
Outer Atom – Inner Carbon Bonds     
 H(8)  -  C(8) 0.06 1.944 -20.544 
Table 3.1.3 
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Compound 2 
Name: 
HS-P53-1  
methyl 1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate 
Affinity:  
Ki = 4,400 ± 764  nM 
ORTEP: 
 
Figure 3.1.4 
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ESP Maps:
 
Figure 3.1.5 
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Figure 3.1.6 
 
Refinement Note: 
Residual maps are flat throughout the model. 
Crystal Data Table: 
General Sample Information 
Molecular formula C16 N3 O2 Cl2 H11 
Formula weight 348.18 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Rhombohedral R 
Space Group R3c 
Cell Dimensions   
a (Å) 34.6620 
b (Å) 34.6620 
c (Å) 6.8889 j 90.000  90.000 
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 120.000 
Volume 7167.83 
Density 1.452 Mg/m3 
Absorption coefficient 0.420 mm-1 
Crystal size (mm) 0.17 x 0.2 x 0.4 
(sinθ/λ)max (Å-1) 1.0 
Unique reflections 11,923 [R(int) = 0.0240] 
Average redundancy 8.74 
Completeness to (sinθ/λ)max 93.7 
Absorption correction Empirical (tmin = 0.850, tmax = 0.932) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters 10595 / 1 / 252 
Goodness-or-fit on F2 1.067 
Final R indices [I>2xI R1 = 0.0280  
R indices (all data) R1 = 0.0357, wR2 = 0.0741 
Largest difference peak and trough 0.585 and -0.175  · Å ; 
Nref/Nv 42.04 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 5787 / 0 / 432 
Goodness-or-fit (GoF) on F 2.271 
Final R indices [I>2xI R1 = 0.0187, wRF = 0.0117 
R indices (all data) R1 = 0.0311  
Largest difference peak and trough 0.545 and -0.482  · Å ; 
Nref/Nv 13.43 
                           Table 3.1.4 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.7469E+01 -4.6992E-01 29.1814 
Cl(2) 1.7474E+01 -4.7491E-01 30.5684 
O(1) 9.0878E+00 -1.0878E+00 13.4914 
O(2) 9.1861E+00 -1.1861E+00 18.5752 
N(1) 7.5168E+00 -5.1686E-01 13.8900 
N(2) 7.1313E+00 -1.3137E-01 13.2726 
N(3) 7.6782E+00 -6.7822E-01 9.5679 
C(1) 5.7605E+00 2.3940E-01 10.4829 
C(2) 4.3780E+00 1.6219E+00 4.7353 
C(3) 5.5392E+00 4.6073E-01 8.2860 
C(4) 5.4857E+00 5.1427E-01 8.3055 
C(5) 5.7896E+00 2.1037E-01 9.1551 
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C(6) 6.1185E+00 -1.1853E-01 11.6227 
C(7) 6.0765E+00 -7.6543E-02 12.1608 
C(8) 6.1089E+00 -1.0896E-01 10.6418 
C(9) 6.0773E+00 -7.7335E-02 12.4339 
C(10) 6.1213E+00 -1.2135E-01 12.3970 
C(11) 5.6478E+00 3.5216E-01 8.9513 
C(12) 6.0937E+00 -9.3772E-02 12.0944 
C(13) 6.0783E+00 -7.8375E-02 12.3240 
C(14) 6.1097E+00 -1.0979E-01 10.2023 
C(15) 6.0697E+00 -6.9795E-02 10.9717 
C(16) 6.1053E+00 -1.0532E-01 11.5214 
H(1A) 8.6285E-01 1.3714E-01 5.8559 
H(1B) 8.6695E-01 1.3304E-01 5.9930 
H(1C) 8.4726E-01 1.5273E-01 5.9503 
H(6) 8.8456E-01 1.1543E-01 5.9530 
H(7) 9.1318E-01 8.6814E-02 6.0942 
H(9) 9.1058E-01 8.9410E-02 6.3823 
H(10) 8.7338E-01 1.2661E-01 5.6343 
H(12) 8.9074E-01 1.0925E-01 6.1673 
H(13) 9.0948E-01 9.0514E-02 6.5917 
H(15) 9.1180E-01 8.8193E-02 6.2636 
H(16) 8.8539E-01 1.1460E-01 5.7657 
           Table 3.1.5 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Monochlorophenyl Ring [N(3) 
connectivity] 
 
Inner Carbon Bonds     
 C(11)  -  C(12) 0.18 2.163 -18.365 
C(12)  -  C(13) 0.11 2.183 -19.854 
C(13)  -  C(14) 0.20 2.226 -20.453 
C(14)  -  C(15) 0.19 2.237 -20.709 
C(15)  -  C(16) 0.11 2.181 -19.763 
C(16)  -  C(11) 0.24 2.203 -20.143 
Outer Atom – Inner Carbon Bonds     
 N(3)  -  C(11) 0.06 1.957 -17.546 
H(12)  -  C(12) 0.07 1.816 -18.856 
H(13)  -  C(13) 0.08 1.852 -19.820 
Cl(2)  -  C(14) 0.07 1.415 -3.316 
H(15)  -  C(15) 0.08 1.851 -19.820 
H(16)  -  C(16) 0.06 1.813 -18.715 
Monochlorophenyl Ring [C(4) 
connectivity] 
 
 Inner Carbon Bonds     
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 C(5)  -  C(6) 0.16 2.204 -21.043 
C(6)  -  C(7) 0.11 2.187 -19.849 
C(7)  -  C(8) 0.19 2.228 -20.445 
C(8)  -  C(9) 0.20 2.220 -20.333 
C(9)  -  C(10) 0.11 2.177 -19.608 
C(10)  -  C(5) 0.12 2.181 -19.908 
Outer Atom – Inner Carbon Bonds     
 C(4)  -  C(5) 0.08 1.903 -17.673 
H(6)  -  C(6) 0.06 1.815 -18.723 
H(7)  -  C(7) 0.08 1.852 -19.830 
Cl(1)  -  C(8) 0.07 1.406 -3.191 
H(9)  -  C(9) 0.08 1.852 -19.833 
H(10)  -  C(10) 0.06 1.800 -18.273 
Ester Side Chain  
 C(2)  -  C(3) 0.09 1.874 -15.757 
O(2)  -  C(2) 0.10 3.097 -27.216 
O(1)  -  C(2) 0.01 2.280 -24.399 
C(1)  -  O(1) 0.11 1.648 -11.235 
H(1A)  -  C(1) 0.17 1.838 -20.882 
H(1B)  -  C(1) 0.14 1.868 -21.278 
H(1C)  -  C(1) 0.17 1.854 -20.822 
Triazole Ring   
 N(1)  -  N(2) 0.08 2.934 -16.566 
N(2)  -  N(3) 0.08 2.498 -10.459 
N(3)  -  C(4) 0.06 2.130 -18.820 
C(4)  -  C(3) 0.25 2.205 -22.697 
C(3)  -  N(1) 0.19 2.309 -24.190 
Table 3.1.6 
  
  
Compound 3 
Name: 
HS-P57-2 
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)
Affinity:  
Ki = 1,400 ± 266 nM 
ORTEP: 
Figure 3.1.7 
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-1H-1,2,3-triazole 
 
 
 
 
59 
 
ESP Maps: 
 
Figure 3.1.8 
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Figure 3.1.9 
 
Refinement Note: 
A peak of 4 contours (0.40  · Å ;) about Cl(3) in the C(3), C(5), and C(7) plane is present.  Residuals 
elsewhere are a slightly bumpy though not severe.  
Crystal Data Table: 
General Sample Information 
Molecular formula C14 N3 Cl3 H8 
Formula weight 324.59 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Monoclinic P 
Space Group P2(1)/c 
Cell Dimensions   
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a (Å) 19.8341 
b (Å) 5.5235 
c (Å) 12.3196 j 90.000  98.266  90.000 
Volume 1335.64 
Density 1.614 Mg/m3 
Absorption coefficient  0.676 mm-1 
Crystal size (mm) 0.25 x 0.5 x 0.6 
(sinθ/λ)max (Å-1) 1.02 
Unique reflections 10,494 [R(int) = 0.0224] 
Average redundancy 8.24 
Completeness to (sinθ/λ)max 86.7 
Absorption correction Empirical (tmin = 0.668, tmax = 0.849) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters   9051 / 0 / 213 
Goodness-or-fit on F2 1.116 
Final R indices [I>2xI R1 = 0.0363 
R indices (all data) R1 = 0.0447, wR2 = 0.1073 
Largest difference peak and trough 0.769 and -0.439  · Å ; 
Nref/Nv 42.49 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 9199 / 0 / 447 
Goodness-or-fit (GoF) on F 3.920 
Final R indices [I>2xI R1 = 0.0277, wRF = 0.0258 
R indices (all data) R1 = 0.0485  
Largest difference peak and trough 0.498 and-0.345  · Å ; 
Nref/Nv 20.63 
                           Table 3.1.7 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.7231E+01 -2.3167E-01 26.7779 
Cl(2) 1.7218E+01 -2.1890E-01 29.2742 
Cl(3) 1.7157E+01 -1.5785E-01 28.2134 
N(1) 7.4468E+00 -4.4684E-01 14.3374 
N(2) 7.1752E+00 -1.7521E-01 12.9334 
N(3) 7.6429E+00 -6.4295E-01 9.6717 
C(1) 5.9330E+00 6.6974E-02 11.2789 
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C(2) 5.8213E+00 1.7866E-01 9.8928 
C(3) 5.9237E+00 7.6280E-02 9.9953 
C(4) 6.0502E+00 -5.0206E-02 11.9547 
C(5) 5.9847E+00 1.5281E-02 11.7414 
C(6) 5.9878E+00 1.2166E-02 10.1909 
C(7) 5.9905E+00 9.4812E-03 11.4347 
C(8) 6.0473E+00 -4.7363E-02 11.9544 
C(9) 5.6870E+00 3.1294E-01 8.2869 
C(10) 6.1273E+00 -1.2736E-01 10.0227 
C(11) 6.1207E+00 -1.2070E-01 11.6779 
C(12) 6.1772E+00 -1.7722E-01 10.0412 
C(13) 5.8937E+00 1.0628E-01 11.1397 
C(14) 6.1455E+00 -1.4558E-01 11.6040 
H(1) 7.4877E-01 2.5122E-01 5.0537 
H(4) 7.6339E-01 2.3660E-01 5.3410 
H(5) 7.9047E-01 2.0952E-01 5.8600 
H(7) 7.8887E-01 2.1112E-01 5.5030 
H(8) 7.7557E-01 2.2442E-01 4.6838 
H(11) 7.9127E-01 2.0872E-01 5.4597 
H(13) 7.7151E-01 2.2848E-01 5.8689 
H(14) 7.9904E-01 2.0095E-01 5.6145 
           Table 3.1.8 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Dichlorophenyl Ring   
Inner Carbon Bonds     
 C(9)  -  C(10) 0.38 2.093 -18.905 
C(10)  -  C(11) 0.24 2.224 -19.383 
C(11)  -  C(12) 0.16 2.333 -20.085 
C(12)  -  C(13) 0.25 2.168 -20.752 
C(13)  -  C(14) 0.10 2.128 -17.048 
C(14)  -  C(9) 0.30 2.402 -22.323 
Outer Atom – Inner Carbon Bonds     
 N(3)  -  C(9) 0.11 1.952 -11.754 
Cl(1)  -  C(10) 0.10 1.448 -1.464 
H(11)  -  C(11) 0.06 1.873 -19.838 
Cl(2)  -  C(12) 0.17 1.294 0.492 
H(13)  -  C(13) 0.10 1.858 -19.270 
H(14)  -  C(14) 0.06 1.859 -20.670 
Monochlorophenyl Ring [C(2) 
connectivity] 
 
 Inner Carbon Bonds     
 C(3)  -  C(4) 0.24 2.140 -18.448 
C(4)  -  C(5) 0.16 2.210 -19.239 
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C(5)  -  C(6) 0.22 2.235 -20.370 
C(6)  -  C(7) 0.27 2.283 -21.433 
C(7)  -  C(8) 0.15 2.200 -19.734 
C(8)  -  C(3) 0.19 2.120 -17.212 
Outer Atom – Inner Carbon Bonds     
 C(2)  -  C(3) 0.09 1.896 -13.621 
H(4)  -  C(4) 0.09 1.828 -18.496 
H(5)  -  C(5) 0.07 1.835 -19.452 
Cl(3)  -  C(6) 0.03 1.402 -2.766 
H(7)  -  C(7) 0.07 1.836 -19.442 
H(8)  -  C(8) 0.09 1.835 -18.712 
Triazole Ring   
Inner Atom Bonds     
 N(1)  -  N(2) 0.02 2.729 -3.122 
N(2)  -  N(3) 0.12 2.475 -4.884 
N(3)  -  C(2) 0.19 2.390 -21.509 
C(2)  -  C(1) 0.30 2.274 -20.685 
C(1)  -  N(1) 0.03 2.356 -16.508 
Outer Atom – Inner Carbon Bonds     
 H(1)  -  C(1) 0.01 1.877 -19.633 
Table 3.1.9 
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Compound 4 
Name: 
HS-P226 
methyl 2-(4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2H-1,2,3-triazol-2-yl)acetate 
Affinity:  
Ki = 885 ± 370 nM 
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ORTEP:
 
Figure 3.1.10 
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ESP Maps:
 
Figure 3.1.11 
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Figure 3.1.12 
 
Refinement Note: 
 A very compact peak of 6 contours (0.60  · Å ;) about the Cl(1) in the C(6), C(8), and C(10) 
plane is present.  Large residuals around Cl(2) and Cl(3) in the C(12), C(14), and C(16) plane that are of 8 
contours (0.80  · Å ;) are present.  No refinement tactic has resolved this issue though the final R(F) 
value is moderately low. 
Crystal Data Table: 
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General Sample Information 
Molecular formula C17 N3 O2 Cl3 H12 
Formula weight 396.65 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Triclinic P 
Space Group P1|  
Cell Dimensions   
a (Å) 7.2954 
b (Å) 8.4996 
c (Å) 15.3575 j 75.490  89.607  73.852 
Volume 883.52 
Density  1.491 Mg/m3 
Absorption coefficient 0.534 mm-1 
Crystal size (mm) 0.5 X 0.5 X 0.6 
(sinθ/λ)max (Å-1) 1.04 
Unique reflections 14,985 [R(int) = 0.0150] 
Average redundancy 7.17 
Completeness to (sinθ/λ)max 89.8% 
Absorption correction Empirical (tmin = 0.674, tmax = 0.776) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters 13864 / 0 / 274 
Goodness-or-fit on F2 1.070 
Final R indices [I>2xI R1 = 0.0347 
R indices (all data) R1 = 0.0372, wR2 = 0.1143 
Largest difference peak and trough 1.545 and -0.696  · Å ; 
Nref/Nv 50.60 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 12967 / 0 / 477 
Goodness-or-fit (GoF) on F 6.1531 
Final R indices [I>2xI R1 = 0.0240, wRF = 0.0289 
R indices (all data) R1 = 0.0286  
Largest difference peak and trough 1.302 and -0.904  · Å ; 
Nref/Nv 27.24 
                           Table 3.1.10 
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Atomic Basin Calculations Table: 
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Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.6914E+01 8.5296E-02 28.6716 
Cl(2) 1.6921E+01 7.8722E-02 26.8121 
Cl(3) 1.6905E+01 9.4336E-02 27.6679 
O(1) 9.1945E+00 -1.1945E+00 13.8231 
O(2) 8.9519E+00 -9.5191E-01 16.9686 
N(1) 7.4497E+00 -4.4972E-01 13.2162 
N(2) 7.3677E+00 -3.6770E-01 8.4886 
N(3) 7.4641E+00 -4.6410E-01 13.7060 
C(1) 5.6817E+00 3.1827E-01 10.2340 
C(2) 4.7370E+00 1.2629E+00 5.0269 
C(3) 5.9733E+00 2.6627E-02 8.5166 
C(4) 5.9088E+00 9.1116E-02 9.0020 
C(5) 5.9175E+00 8.2466E-02 8.8292 
C(6) 5.9383E+00 6.1603E-02 9.5087 
C(7) 6.0465E+00 -4.6533E-02 11.0273 
C(8) 6.0396E+00 -3.9684E-02 11.5461 
C(9) 5.9299E+00 7.0013E-02 8.9381 
C(10) 6.0455E+00 -4.5512E-02 11.8974 
C(11) 6.0492E+00 -4.9280E-02 11.1723 
C(12) 6.0265E+00 -2.6513E-02 9.0245 
C(13) 6.0580E+00 -5.8022E-02 10.4731 
C(14) 6.2844E+00 -2.8444E-01 12.2038 
C(15) 5.9233E+00 7.6621E-02 9.4790 
C(16) 5.8809E+00 1.1907E-01 10.8885 
C(17) 5.9305E+00 6.9480E-02 9.2716 
H(1A) 9.1012E-01 8.9871E-02 5.9781 
H(1B) 9.1828E-01 8.1711E-02 6.8410 
H(1C) 9.1868E-01 8.1311E-02 6.7819 
H(3A) 9.8769E-01 1.2305E-02 6.8188 
H(3B) 9.8860E-01 1.1391E-02 6.5947 
H(7) 9.8898E-01 1.1011E-02 6.5388 
H(8) 9.5686E-01 4.3139E-02 7.5091 
H(10) 9.5660E-01 4.3396E-02 7.2017 
H(11) 9.8678E-01 1.3210E-02 7.1521 
H(13) 9.8905E-01 1.094E-02 7.4168 
H(14) 9.2257E-01 7.7428E-02 7.0968 
H(16) 9.5751E-01 4.2489E-02 6.9677 
           Table 3.1.11 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Ester Side Chain  
 C(3)  -  N(2) 0.06 1.969 -14.173 
H(3A)  -  C(3) 0.13 1.869 -20.106 
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H(3B)  -  C(3) 0.14 1.868 -20.113 
C(2)  -  C(3) 0.17 1.652 -9.177 
O(2)  -  C(2) 0.08 3.373 -34.236 
O(1)  -  C(2) 0.10 2.289 -18.639 
C(1)  -  O(1) 0.10 1.359 7.560 
H(1A)  -  C(1) 0.12 1.698 -10.887 
H(1B)  -  C(1) 0.12 1.700 -10.835 
H(1C)  -  C(1) 0.13 1.696 -10.821 
Dichlorophenyl Ring   
Inner Carbon Bonds     
 C(12)  -  C(13) 0.28 2.087 -15.313 
C(13)  -  C(14) 0.37 2.118 -14.818 
C(14)  -  C(15) 0.25 2.198 -16.216 
C(15)  -  C(16) 0.19 2.215 -19.679 
C(16)  -  C(17) 0.12 2.157 -17.286 
C(17)  -  C(12) 0.22 2.225 -17.616 
Outer Atom – Inner Carbon Bonds     
 C(4)  -  C(12) 0.17 1.896 -12.841 
H(13)  -  C(13) 0.15 1.921 -22.430 
H(14)  -  C(14) 0.10 1.828 -19.223 
Cl(3)  -  C(15) 0.12 1.299 -1.684 
H(16)  -  C(16) 0.05 1.854 -20.088 
Cl(2)  -  C(17) 0.11 1.316 -1.843 
Monochlorophenyl Ring   
 Inner Carbon Bonds     
 C(6)  -  C(7) 0.11 2.124 -16.806 
C(7)  -  C(8) 0.16 2.096 -15.961 
C(8)  -  C(9) 0.14 2.140 -16.925 
C(9)  -  C(10) 0.18 2.154 -17.862 
C(10)  -  C(11) 0.16 2.074 -15.517 
C(11)  -  C(6) 0.12 2.141 -17.416 
Outer Atom – Inner Carbon Bonds     
 C(5)  -  C(6) 0.10 1.897 -12.616 
H(7)  -  C(7) 0.11 1.950 -23.438 
H(8)  -  C(8) 0.06 1.879 -20.701 
Cl(1)  -  C(9) 0.12 1.289 -1.624 
H(10)  -  C(10) 0.06 1.878 -20.686 
H(11)  -  C(11) 0.11 1.944 -23.234 
Triazole Ring   
 N(1)  -  N(2) 0.16 2.784 -6.679 
N(2)  -  N(3) 0.11 2.707 -4.114 
N(3)  -  C(4) 0.13 2.528 -18.302 
C(4)  -  C(5) 0.27 2.119 -14.815 
C(5)  -  N(1) 0.10 2.499 -17.222 
Table 3.1.12  
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Compound 5 
Name: 
HS-P69 
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,3-triazole-4-carboxamide 
Affinity:  
Ki = 590 ± 173 nM 
ORTEP: 
 
Figure 3.1.13 
 
 
 
72 
 
ESP Maps: 
 
Figure 3.1.14 
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Figure 3.1.15 
 
Refinement Note: 
Thermal ellipsoids on the aliphatic ring system are slightly larger than normal but are not extreme.  
Residuals peak about Cl(3) with a sharp 3 contour (0.30  · Å ;) peak in the C(3), C(5), and C(7) plane.  
All other residual peaks are relatively flat. 
Crystal Data Table: 
General Sample Information 
Molecular formula C20 N5 O1 Cl3 H18 
Formula weight 450.74 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Monoclinic P 
Space Group P2(1)/n 
Cell Dimensions   
a (Å) 8.3498 
b (Å) 19.9890 
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c (Å) 13.4454 j 90.000  105.552  90.000 
Volume 2161.93 
Density 1.329 Mg/m3 
Absorption coefficient  0.443 mm-1 
Crystal size (mm) 0.15 x 0.25 x 0.5 
(sinθ/λ)max (Å-1) 0.96 
Unique reflections 15540 [R(int) = 0.0200] 
Average redundancy 9.01 
Completeness to (sinθ/λ)max 97.5% 
Absorption correction Empirical (tmin = 0.660, tmax = 0.749) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters 15540 / 0 / 334 
Goodness-or-fit on F2 1.065 
Final R indices [I>2xI R1 = 0.0389 
R indices (all data) R1 = 0.0476, wR2 = 0.1192 
Largest difference peak and trough 0.670 and -0.766  · Å ; 
Nref/Nv 46.53 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters  13615 / 0 / 655 
Goodness-or-fit (GoF) on F 3.953 
Final R indices [I>2xI R1 = 0.0269, wRF = 0.0228 
R indices (all data) R1 = 0.0429  
Largest difference peak and trough 0.643 and -0.615  · Å ; 
Nref/Nv 20.82 
                           Table 3.1.13 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.7126E+01 -1.2614E-01 27.4994 
Cl(2) 1.7107E+01 -1.0764E-01 27.2432 
Cl(3) 1.7205E+01 -2.0515E-01 28.1845 
O(1) 9.2670E+00 -1.2670E+00 16.5112 
N(1) 7.8233E+00 -8.2330E-01 9.6943 
N(2) 7.3111E+00 -3.1116E-01 13.9753 
N(3) 7.5362E+00 -5.3622E-01 12.4111 
N(4) 7.7590E+00 -7.5907E-01 12.0765 
N(5) 7.4548E+00 -4.5487E-01 9.1919 
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C(1) 5.8449E+00 1.5501E-01 9.5809 
C(2) 5.8093E+00 1.9063E-01 9.2807 
C(3) 6.0876E+00 -8.7691E-02 9.5959 
C(4) 6.1490E+00 -1.4907E-01 11.6209 
C(5) 6.0882E+00 -8.8256E-02 12.2595 
C(6) 6.1569E+00 -1.5695E-01 10.5963 
C(7) 6.0945E+00 -9.4503E-02 12.3772 
C(8) 6.1450E+00 -1.4509E-01 11.6299 
C(9) 5.7908E+00 2.0915E-01 8.4449 
C(10) 6.0469E+00 -4.6935E-02 11.3467 
C(11) 6.1154E+00 -1.1542E-01 11.1428 
C(12) 5.9344E+00 6.5590E-02 10.0780 
C(13) 6.0669E+00 -6.6922E-02 11.3648 
C(14) 6.0424E+00 -4.2441E-02 10.5988 
C(15) 4.8314E+00 1.1685E+00 6.3338 
C(16) 5.9322E+00 6.7773E-02 7.9671 
C(17) 6.2186E+00 -2.1862E-01 8.9206 
C(18) 6.2984E+00 -2.9844E-01 8.9969 
C(19) 6.1954E+00 -1.9542E-01 8.9663 
C(20) 5.9506E+00 4.9355E-02 8.1197 
H(4N) 7.1059E-01 2.8940E-01 3.3731 
H(4) 8.8875E-01 1.1124E-01 5.8917 
H(5) 8.7802E-01 1.2197E-01 6.7450 
H(7) 8.7875E-01 1.2124E-01 6.3137 
H(8) 8.9806E-01 1.0193E-01 5.9166 
H(10) 8.9247E-01 1.0752E-01 6.0385 
H(11) 9.24019E-01 7.5980E-02 5.7393 
H(13) 8.6215E-01 1.3784E-01 5.1649 
H(16A) 8.9963E-01 1.0036E-01 6.9240 
H(16B) 8.8172E-01 1.1827E-01 6.8067 
H(17A) 1.3246E+00 -3.2463E-01 8.6588 
H(17B) 1.3481E+00 -3.4812E-01 8.5305 
H(18A) 1.3322E+00 -3.3225E-01 8.4810 
H(18B) 1.3439E+00 -3.4392E-01 8.2348 
H(19A) 1.3306E+00 -3.3062E-01 8.5717 
H(19B) 1.3332E+00 -3.3327E-01 8.4549 
H(20A) 1.2762E+00 -2.7628E-01 8.0702 
H(20B) 1.2569E+00 -2.5690E-01 7.5668 
           Table 3.1.14 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Dichlorophenyl Ring   
Inner Carbon Bonds     
 C(9)  -  C(10) 0.18 2.254 -19.627 
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C(10)  -  C(11) 0.11 2.182 -17.303 
C(11)  -  C(12) 0.10 2.320 -22.755 
C(12)  -  C(13) 0.09 2.240 -20.791 
C(13)  -  C(14) 0.14 2.230 -19.708 
C(14)  -  C(9) 0.23 2.276 -22.063 
Outer Atom – Inner Carbon Bonds     
 N(1)  -  C(9) 0.08 2.021 -16.412 
H(10)  -  C(10) 0.06 1.841 -17.104 
H(11)  -  C(11) 0.10 1.889 -18.577 
Cl(1)   -  C(12) 0.05 1.310 -0.189 
H(13)  -  C(13) 0.08 1.884 -21.561 
Cl(2)  -  C(14) 0.01 1.347 -0.189 
Monochlorophenyl Ring  
 Inner Carbon Bonds     
 C(3)  -  C(4) 0.12 2.194 -18.078 
C(4)  -  C(5) 0.17 2.256 -21.410 
C(5)  -  C(6) 0.16 2.212 -19.690 
C(6)  -  C(7) 0.14 2.212 -19.352 
C(7)  -  C(8) 0.17 2.254 -21.344 
C(8)  -  C(3) 0.11 2.193 -17.893 
Outer Atom – Inner Carbon Bonds     
 C(2)  -  C(3) 0.06 1.982 -15.025 
H(4)  -  C(4) 0.07 1.850 -18.354 
H(5)  -  C(5) 0.02 1.737 -15.494 
Cl(3)  -  C(6) 0.02 1.385 -2.581 
H(7)  -  C(7) 0.03 1.735 -15.462 
H(8)  -  C(8) 0.07 1.849 -18.313 
Aliphatic Ring  
 Inner Atom Bonds     
 N(5)  -  C(16) 0.06 1.924 -14.120 
C(16)  -  C(17) 0.08 1.764 -16.350 
C(17)  -  C(18) 0.09 1.893 -19.408 
C(18)   -  C(19) 0.03 1.871 -18.750 
C(19)  -  C(20) 0.09 1.770 -16.391 
C(20)  -  N(5) 0.04 1.919 -14.565 
Outer Atom – Inner Carbon Bonds     
 N(4)  -  N(5) 0.06 2.214 -3.568 
H(16A)  -  C(16) 0.07 1.707 -17.910 
H(16B)  -  C(16) 0.07 1.692 -17.775 
H(17A)  -  C(17) 0.03 1.727 -18.365 
H(17B)  -  C(17) 0.02 1.737 -18.357 
H(18A)  -  C(18) 0.03 1.727 -18.307 
H(18B)  -  C(18) 0.03 1.731 -18.203 
H(19A)  -  C(19) 0.02 1.726 -18.347 
H(19B)  -  C(19) 0.04 1.723 -18.237 
H(20A)  -  C(20) 0.08 1.701 -17.782 
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H(20B)  -  C(20) 0.08 1.698 -17.910 
Amide Linker  
 C(15)  -  C(1) 0.20 1.925 -15.800 
O(1)  -  C(15) 0.01 3.137 -41.279 
N(4)  -  C(15) 0.24 2.453 -24.384 
H(4N)  -  N(4) 0.11 2.291 -33.390 
Triazole Ring   
 N(3)  -  N(2) 0.13 3.008 -15.822 
N(2)  -  N(1) 0.17 2.641 -10.495 
N(1)  -  C(2) 0.09 2.273 -21.808 
C(2)  -  C(1) 0.22 2.197 -17.003 
C(1)  -  N(3) 0.08 2.426 -20.194 
Table 3.1.15 
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Compound 6 
Name: 
HS-P183 
methyl 2-(5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)acetate 
Affinity:  
Ki = 250 ± 86 nM 
ORTEP: 
 
Figure 3.1.16 
 
ESP Maps: 
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Figure 3.1.17 
 
 
80 
 
 
Figure 3.1.18 
Refinement Note: 
Residual density peaks at 5 contours (0.50  · Å ;) about Cl(3) in the plane of C(4), Cl(3), and Cl(2).  All 
other residual density is flat. 
Crystal Data Table: 
General Sample Information 
Molecular formula C17 N3 O2 Cl3 H12 
Formula weight 396.65 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Monoclinic P 
Space Group P2(1)/n 
Cell Dimensions   
a (Å) 10.8507 
b (Å) 7.3608 
c (Å) 21.5139 j 90.000 
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 103.854  90.000 
Volume 1668.32 
Density 1.579 Mg/m3 
Absorption coefficient 0.566 mm-1 
Crystal size (mm) 0.15 X 0.3 X 0.5 
(sinθ/λ)max (Å-1) 1.11 
Unique reflections 18,220 [R(int) = 0.0228] 
Average redundancy 6.37 
Completeness to (sinθ/λ)max 94.8% 
Absorption correction Empirical (tmin = 0.728, tmax = 0.920) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters  15027 / 0 / 274 
Goodness-or-fit on F2 1.046 
Final R indices [I>2xI R1 = 0.0333 
R indices (all data) R1 = 0.0426, wR2 = 0.1037 
Largest difference peak and trough 0.848 and -0.300  · Å ; 
Nref/Nv 54.84 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 15904 / 0 / 501 
Goodness-or-fit (GoF) on F 2.524 
Final R indices [I>2xI R1 = 0.0256, wRF = 0.0205 
R indices (all data) R1 = 0.0440  
Largest difference peak and trough 0.561 and -0.488  · Å ; 
Nref/Nv 31.81 
                           Table 3.1.16 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.7086E+01 -8.6344E-02 28.1119 
Cl(2) 1.7098E+01 -9.8775E-02 27.6786 
Cl(3) 1.7092E+01 -9.2424E-02 28.2529 
O(1) 9.0191E+00 -1.0191E+00 16.8827 
O(2) 9.1350E+00 -1.1350E+00 13.4959 
N(1) 7.6711E+00 -6.7111E-01 9.3639 
N(2) 7.1654E+00 -1.6545E-01 13.2928 
N(3) 7.5377E+00 -5.3770E-01 13.4828 
C(1) 5.8356E+00 1.6437E-01 9.2292 
C(2) 5.7611E+00 2.3882E-01 9.0668 
C(3) 5.9834E+00 1.6538E-02 9.5898 
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C(4) 6.0360E+00 -3.6092E-02 11.9502 
C(5) 6.0299E+00 -2.9968E-02 11.6122 
C(6) 6.1374E+00 -1.3745E-01 10.2817 
C(7) 6.1416E+00 -1.4164E-01 11.3091 
C(8) 6.0151E+00 -1.5112E-02 9.8932 
C(9) 6.1112E+00 -1.1125E-01 9.6945 
C(10) 6.0651E+00 -6.5136E-02 11.4107 
C(11) 6.1447E+00 -1.4473E-01 11.6147 
C(12) 6.0879E+00 -8.7906E-02 9.9838 
C(13) 6.1530E+00 -1.5306E-01 11.9459 
C(14) 6.0626E+00 -6.2644E-02 11.6832 
C(15) 5.9309E+00 6.9023E-02 8.3393 
C(16) 4.6854E+00 1.3145E+00 5.6351 
C(17) 5.9511E+00 4.8811E-02 11.0934 
H(4) 8.9065E-01 1.0934E-01 6.1306 
H(5) 8.6624E-01 1.3375E-01 5.9002 
H(7) 8.6380E-01 1.3619E-01 5.6817 
H(10) 8.8282E-01 1.1717E-01 5.9032 
H(11) 8.8214E-01 1.1785E-01 5.4016 
H(13) 8.8087E-01 1.1912E-01 6.0061 
H(14) 8.8776E-01 1.1223E-01 6.1646 
H(15A) 8.7054E-01 1.2945E-01 5.2443 
H(15B) 8.6692E-01 1.3307E-01 5.8002 
H(17A) 1.2592E+00 -2.5925E-01 7.0517 
H(17B) 1.2617E+00 -2.6174E-01 7.5697 
H(17C) 1.3000E+00 -3.0003E-01 7.5941 
           Table 3.1.17 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Ester Side Chain  
 C(15)  -  N(1) 0.06 1.899 -12.816 
H(15A)  -  C(15) 0.13 1.804 -17.572 
H(15B)  -  C(15) 0.13 1.806 -17.697 
C(16)  -  C(15) 0.05 1.876 -15.677 
O(1)  -  C(16) 0.03 3.254 -50.752 
O(2)  -  C(16) 0.06 2.440 -30.962 
C(17)  -  O(2) 0.00 1.725 -15.020 
H(17A)  -  C(17) 0.10 1.827 -21.190 
H(17B)  -  C(17) 0.09 1.829 -21.301 
H(17C)  -  C(17) 0.06 1.900 -23.132 
Monochlorophenyl Ring   
Inner Carbon Bonds     
 C(9)  -  C(10) 0.15 2.158 -17.377 
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C(10)  -  C(11) 0.16 2.200 -18.621 
C(11)   -  C(12) 0.18 2.245 -20.319 
C(12)  -  C(13) 0.18 2.247 -20.460 
C(13)  -  C(14) 0.16 2.204 -18.713 
C(14)  -  C(9) 0.15 2.166 -17.617 
Outer Atom – Inner Carbon Bonds     
 C(1)  -  C(9) 0.02 1.866 -12.375 
H(10)  -  C(10) 0.04 1.878 -20.819 
H(11)  -  C(11) 0.04 1.878 -20.611 
Cl(1)  -  C(12) 0.02 1.289 0.352 
H(13)  -  C(13) 0.04 1.877 -20.563 
H(14)  -  C(14) 0.04 1.882 -20.939 
Dichlorophenyl Ring   
 Inner Carbon Bonds     
 C(3)  -  C(4) 0.19 2.134 -18.506 
C(4)  -  C(5) 0.20 2.194 -19.576 
C(5)  -  C(6) 0.24 2.195 -18.722 
C(6)  -  C(7) 0.21 2.217 -18.108 
C(7)  -  C(8) 0.29 2.233 -21.146 
C(8)  -  C(3) 0.12 2.144 -16.652 
Outer Atom – Inner Carbon Bonds     
 C(2)  -  C(3) 0.12 1.931 -16.061 
H(4)  -  C(4) 0.07 1.867 -20.743 
H(5)  -  C(5) 0.05 1.817 -18.994 
Cl(3)  -  C(6) 0.12 1.300 -1.236 
H(7)  -  C(7) 0.05 1.856 -19.990 
Cl(2)  -  C(8) 0.08 1.313 -1.463 
Triazole Ring   
 N(3)  -  N(2) 0.14 2.908 -14.508 
N(2)  -  N(1) 0.29 2.682 -10.333 
N(1)  -  C(1) 0.15 2.255 -19.693 
C(1)  -  C(2) 0.26 2.166 -16.235 
C(2)  -  N(3) 0.21 2.376 -20.029 
Table 3.1.18 
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Compound 7 
Name: 
HS-P57-7 
cyclohexyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate 
Affinity:  
Ki = 240 nM ± 83.5 
ORTEP: 
 
Figure 3.1.19 
 
ESP Maps: 
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Figure 3.1.20 
 
 
Figure 3.1.21 
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Refinement Note: 
 The refinement of this molecule has left clean residuals, with a sharp peak of just barely 3 
contours (0.30  · Å ;) about Cl(1), and a low R(F) value. 
Crystal Data Table: 
General Sample Information 
Molecular formula C21 N3 O2 Cl3 H18 
Formula weight 450.73 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Triclinic P 
Space Group P1|  
Cell Dimensions   
a (Å) 10.6088 
b (Å) 10.9412 
c (Å) 11.0942 j 115.755  98.247  110.068 
Volume 1022.19 
Density 1.464 Mg/m3 
Absorption coefficient 0.472 mm-1 
Crystal size (mm) 0.07 x 0.2 x 0.5 
(sinθ/λ)max (Å-1) 1.11 
Unique reflections 10,740 [R(int) = 0.0239] 
Average redundancy 7.51 
Completeness to (sinθ/λ)max 99.9% 
Absorption correction Empirical (tmin = 0.765, tmax = 0.968) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters 9599 / 0 / 334 
Goodness-or-fit on F2 0.833 
Final R indices [I>2xI R1 = 0.0312 
R indices (all data) R1 = 0.0365, wR2 = 0.0994 
Largest difference peak and trough 0.804 and -0.396  · Å ; 
Nref/Nv 28.74 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
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Data(I>2xI/restraints/parameters 14504 / 0 / 666 
Goodness-or-fit (GoF) on F 2.595 
Final R indices [I>2xI R1 = 0.0237, wRF = 0.0207 
R indices (all data) R1 = 0.0588  
Largest difference peak and trough 0.756 and -0.575  · Å ; 
Nref/Nv 21.8105 
                           Table 3.1.19 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.7187E+01 -1.8768E-01 28.1978 
Cl(2) 1.6892E+01 1.0712E-01 26.8137 
Cl(3) 1.6947E+01 5.2032E-02 28.1417 
O(1) 9.1572E+00 -1.1572E+00 13.6930 
O(2) 9.1217E+00 -1.1217E+00 16.1283 
N(1) 7.5493E+00 -5.4935E-01 14.7047 
N(2) 7.1083E+00 -1.0834E-01 13.6161 
N(3) 7.7248E+00 -7.2482E-01 9.2860 
C(1) 5.8820E+00 1.1797E-01 7.9462 
C(2) 5.9014E+00 9.8596E-02 7.3835 
C(3) 5.9876E+00 1.2362E-02 8.4555 
C(4) 5.8350E+00 1.6496E-01 7.2782 
C(5) 6.1307E+00 -1.3074E-01 9.4510 
C(6) 5.6230E+00 3.7698E-01 5.8257 
C(7) 4.8374E+00 1.1625E+00 6.0768 
C(8) 5.7886E+00 2.1139E-01 9.0700 
C(9) 5.7996E+00 2.0031E-01 8.8291 
C(10) 5.9769E+00 2.3042E-02 9.9372 
C(11) 5.9444E+00 5.5543E-02 10.6539 
C(12) 6.0098E+00 -9.8383E-03 11.6387 
C(13) 6.0070E+00 -7.0594E-03 10.0712 
C(14) 5.9220E+00 7.7974E-02 10.9281 
C(15) 6.0585E+00 -5.8533E-02 10.9108 
C(16) 5.8444E+00 1.5551E-01 9.2285 
C(17) 6.0552E+00 -5.5256E-02 9.4447 
C(18) 5.9374E+00 6.2533E-02 10.4233 
C(19) 5.9244E+00 7.5516E-02 9.6577 
C(20) 5.8818E+00 1.1813E-01 11.0678 
C(21) 5.8877E+00 1.1229E-01 10.7638 
H(1A) 1.0191E+00 -1.9191E-02 6.9418 
H(1B) 1.0233E+00 -2.3378E-02 7.1390 
H(2A) 1.0513E+00 -5.1323E-02 7.5162 
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H(2B) 1.0592E+00 -5.9222E-02 7.6902 
H(3A) 9.7625E-01 2.3747E-02 6.6999 
H(3B) 9.7409E-01 2.5901E-02 6.8970 
H(4A) 1.0566E+00 -5.6644E-02 7.3155 
H(4B) 1.0710E+00 -7.1041E-02 7.6686 
H(5A) 9.2235E-01 7.7642E-02 6.9044 
H(5B) 9.0844E-01 9.1550E-02 6.4976 
H(6) 1.1432E+00 -1.4320E-01 6.8363 
H(11) 1.3982E+00 -3.9829E-01 7.5044 
H(12) 1.3975E+00 -3.9751E-01 7.5412 
H(14) 1.3775E+00 -3.7758E-01 8.2842 
H(15) 1.3811E+00 -3.8113E-01 7.5776 
H(18) 1.4074E+00 -4.0749E-01 7.0299 
H(20) 1.3603E+00 -3.6038E-01 7.2879 
H(21) 1.3958E+00 -3.9581E-01 7.4395 
           Table 3.1.20 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Dichlorophenyl Ring   
Inner Carbon Bonds     
 C(16)  -  C(17) 0.29 2.293 -20.110 
C(17)  -  C(18) 0.15 2.144 -17.184 
C(18)  -  C(19) 0.08 2.148 -16.578 
C(19)  -  C(20) 0.20 2.257 -19.641 
C(20)  -  C(21) 0.12 2.204 -21.656 
C(21)  -  C(16) 0.10 2.133 -15.516 
Outer Atom – Inner Carbon Bonds     
 N(3)  -  C(16) 0.04 1.992 -16.079 
Cl(2)  -  C(17) 0.15 1.334 1.398 
H(18)  -  C(18) 0.00 2.054 -21.287 
Cl(3)  -  C(19) 0.09 1.344 -2.739 
H(20)  -  C(20) 0.02 1.936 -19.490 
H(21)  -  C(21) 0.05 1.990 -19.623 
Monochlorophenyl Ring  
 Inner Carbon Bonds     
 C(10)  -  C(11) 0.14 2.220 -19.496 
C(11)  -  C(12) 0.01 2.185 -16.732 
C(12)  -  C(13) 0.18 2.307 -23.274 
C(13)  -  C(14) 0.18 2.275 -20.497 
C(14)  -  C(15) 0.01 2.102 -15.232 
C(15)  -  C(10) 0.22 2.300 -21.678 
Outer Atom – Inner Carbon Bonds     
 C(9)  -  C(10) 0.12 1.844 -11.414 
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H(11)  -  C(11) 0.11 2.009 -21.072 
H(12)  -  C(12) 0.00 2.020 -21.266 
Cl(1)  -  C(13) 0.18 1.215 1.682 
H(14)  -  C(14) 0.06 1.991 -20.999 
H(15)  -  C(15) 0.05 1.979 -20.308 
Aliphatic Ring  
 Inner Carbon Bonds     
 C(6)   -  C(1) 0.05 1.786 -14.540 
C(1)   -  C(2) 0.03 1.659 -13.140 
C(2)   -  C(3) 0.09 1.817 -17.141 
C(3)   -  C(4) 0.03 1.766 -15.158 
C(4)   -  C(5) 0.03 1.616 -11.419 
C(5)  -  C(6) 0.12 1.769 -13.746 
Outer Atom – Inner Carbon Bonds     
 O(1)  -  C(6) 0.05 1.691 -16.832 
H(6)  -  C(6) 0.13 1.981 -21.556 
H(1A)  -  C(1) 0.01 1.702 -13.787 
H(1B)  -  C(1) 0.01 1.713 -13.921 
H(2A)  -  C(2) 0.06 1.776 -15.965 
H(2B)  -  C(2) 0.05 1.776 -16.016 
H(3A)  -  C(3) 0.04 1.649 -12.835 
H(3B)  -  C(3) 0.05 1.648 -12.893 
H(4A)  -  C(4) 0.05 1.760 -16.021 
H(4B)  -  C(4) 0.05 1.778 -15.996 
H(5A)  -  C(5) 0.06 1.597 -10.666 
H(5B)  -  C(5) 0.08 1.573 -9.990 
Ester Linker  
 C(7)  -  C(8) 0.21 1.948 -16.139 
O(2)  -  C(7) 0.12 3.312 -45.894 
O(1)  -  C(7) 0.19 2.364 -25.758 
Triazole Ring   
 N(1)  -  N(2) 0.14 2.969 -16.102 
N(2)  -  N(3) 0.35 2.383 -3.240 
N(3)  -  C(9) 0.15 2.328 -22.022 
C(9)  -  C(8) 0.36 2.211 -17.928 
C(8)  -  N(1) 0.26 2.332 -19.069 
Table 3.1.21 
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Compound 8 
Name: 
HS-P57-3 
ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate 
Affinity:  
Ki = 180 nM ± 26.7 
 
ORTEP:
 
Figure 3.1.22 
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ESP Maps:
 
Figure 3.1.23 
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Figure 3.1.24 
 
Refinement Note: 
 The kappa assignments for this molecule are very unconventional.  The final R(F) is very low and 
residual peak are minimal except about CL(1) which are very sharp and max out at 8 contours (0.80 
 · Å ;).  Deformation densities look normal.  And other properties ate regular. 
Crystal Data Table: 
General Sample Information 
Molecular formula C17 N3 O2 Cl3 H12 
Formula weight 396.65 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Monoclinic C 
Space Group Cc 
Cell Dimensions   
a (Å) 10.8385 
b (Å) 25.1300 
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c (Å) 8.2357 j 90.000  128.795  90.000 
Volume 1748.31 
Density 1.507 Mg/m3 
Absorption coefficient 0.540 mm-1 
Crystal size (mm) 0.2 x 0.5 x 0.5 
(sinθ/λ)max (Å-1) 1.06 
Unique reflections 12,952 [R(int) = 0.0166] 
Average redundancy 4.4 
Completeness to (sinθ/λ)max 91.6% 
Absorption correction Empirical (tmin = 0.774, tmax = 0.900) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters 12,952 / 2 / 274 
Goodness-or-fit on F2 1.061 
Final R indices [I>2xI R1 = 0.0357 
R indices (all data) R1 = 0.0451, wR2 = 0.1045 
Largest difference peak and trough 0.908 and -0.719  · Å ; 
Nref/Nv 47.27 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 6248 / 0 / 429 
Goodness-or-fit (GoF) on F 2.1025 
Final R indices [I>2xI R1 = 0.0200, wRF = 0.0180 
R indices (all data) R1 = 0.0378  
Largest difference peak and trough 2.491 and -2.117  · Å ; 
Nref/Nv 14.5981 
                           Table 3.1.22 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1) 1.7290E+01 -2.9034E-01 29.3937 
Cl(2) 1.7304E+01 -3.0403E-01 28.3342 
Cl(3) 1.7291E+01 -2.9186E-01 28.8981 
O(1) 9.0661E+00 -1.0661E+00 11.9877 
O(2) 9.4109E+00 -1.4109E+00 17.7016 
N(1) 7.4526E+00 -4.5265E-01 14.1335 
N(2) 7.3378E+00 -3.3789E-01 14.3597 
N(3) 7.6890E+00 -6.8906E-01 9.2975 
C(1) 5.9117E+00 8.8248E-02 7.7551 
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C(2) 5.7257E+00 2.7428E-01 7.1480 
C(3) 4.7867E+00 1.2132E+00 5.3939 
C(4) 5.8501E+00 1.4985E-01 8.8139 
C(5) 5.5417E+00 4.5820E-01 7.9608 
C(6) 5.8976E+00 1.0234E-01 9.6066 
C(7) 5.9184E+00 8.1535E-02 10.6373 
C(8) 6.0375E+00 -3.7506E-02 11.1976 
C(9) 5.9471E+00 5.2836E-02 10.2848 
C(10) 6.0653E+00 -6.5301E-02 11.2581 
C(11) 5.8956E+00 1.04317E-01 10.6930 
C(12) 6.1353E+00 -1.3531E-01 9.5484 
C(13) 5.7016E+00 2.9835E-01 10.3741 
C(14) 6.0563E+00 -5.6347E-02 11.3237 
C(15) 5.9403E+00 5.9658E-02 10.3412 
C(16) 6.0331E+00 -3.3115E-02 10.9012 
C(17) 5.8900E+00 1.0994E-01 9.9109 
H(1A) 7.9227E-01 2.0772E-01 6.2015 
H(1B) 8.1653E-01 1.8346E-01 5.7849 
H(1C) 8.1514E-01 1.8485E-01 6.1276 
H(2A) 7.5542E-01 2.4457E-01 5.6343 
H(2B) 7.7012E-01 2.2987E-01 5.2033 
H(7) 8.5173E-01 1.4826E-01 6.0062 
H(8) 8.2818E-01 1.7181E-01 6.4194 
H(10) 8.2867E-01 1.7132E-01 5.9990 
H(11) 8.5535E-01 1.4464E-01 5.8373 
H(13) 8.407E-01 1.5929E-01 6.4671 
H(14) 8.2571E-01 1.7428E-01 6.7000 
H(16) 8.3088E-01 1.6911E-01 6.2724 
           Table 3.1.23 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Dichlorophenyl Ring   
Inner Carbon Bonds     
 C(12)  -  C(13) 0.40 2.360 -25.496 
C(13)  -  C(14) 0.24 2.198 -21.315 
C(14)  -  C(15) 0.25 2.282 -22.763 
C(15)  -  C(16) 0.19 2.270 -21.736 
C(16)  -  C(17) 0.26 2.323 -24.326 
C(17)  -  C(12) 0.18 2.268 -18.943 
Outer Atom – Inner Carbon Bonds     
 N(3)  -  C(12) 0.09 2.100 -17.885 
H(13)  -  C(13) 0.04 1.729 -15.106 
H(14)  -  C(14) 0.05 1.792 -16.596 
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Cl(3)  -  C(15) 0.00 1.347 -0.636 
H(16)  -  C(16) 0.05 1.799 -17.031 
Cl(2)  -  C(17) 0.01 1.358 -0.732 
Monochlorophenyl Ring  
 Inner Carbon Bonds     
 C(6)  -  C(7) 0.10 2.147 -18.664 
C(7)  -  C(8) 0.23 2.235 -21.391 
C(8)  -  C(9) 0.19 2.256 -21.247 
C(9)  -  C(10) 0.26 2.322 -23.883 
C(10)  -  C(11) 0.21 2.237 -21.095 
C(11)  -  C(6) 0.05 2.120 -17.251 
Outer Atom – Inner Carbon Bonds     
 C(5)  -  C(6) 0.04 1.794 -13.118 
H(7)  -  C(7) 0.04 1.765 -15.702 
H(8)  -  C(8) 0.05 1.787 -16.515 
Cl(1)  -  C(9) 0.00 1.333 -0.469 
H(10)  -  C(10) 0.05 1.792 -16.612 
H(11)  -  C(11) 0.04 1.761 -15.672 
Ester Side Chain  
 C(3)  -  C(4) 0.21 1.886 -12.017 
O(2)  -  C(3) 0.07 3.053 -5.585 
O(1)  -  C(3) 0.18 2.416 -16.786 
C(2)  -  O(1) 0.05 1.711 -6.536 
H(2A)  -  C(2) 0.05 1.809 -19.934 
H(2B)  -  C(2) 0.05 1.828 -20.281 
C(1)  -  C(2) 0.13 1.785 -14.771 
H(1A)  -  C(1) 0.03 1.825 -20.293 
H(1B)  -  C(1) 0.02 1.850 -20.618 
H(1C)  -  C(1) 0.02 1.841 -20.573 
Triazole Ring   
 N(1)  -  N(2) 0.17 2.873 -11.403 
N(2)  -  N(3) 0.13 2.574 -11.528 
N(3)  -  C(5) 0.12 2.273 -21.722 
C(5)  -  C(4) 0.15 2.331 -23.614 
C(4)  -  N(1) 0.09 2.256 -19.016 
Table 3.1.24 
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Compound 9 
Name: 
AVG-229Ph 
phenyl 1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-1H-1,2,3-triazole-4-carboxylate 
Affinity:  
Ki = 170 nM  
ORTEP: 
 
Figure 3.1.25 
 
ESP Maps: 
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Figure 3.1.26 
 
Figure 3.1.27 
 
Refinement Note: 
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 Residual density is large about Cl(1) and medium about Cl(2).  To reduce these residual peaks 
anisotropic-anharmonic temperature factors were applied to Cl(1).  This method was ineffective for 
Cl(2). 
Crystal Data Table: 
General Sample Information 
Molecular formula C21 N3 O2 Cl2 F1 H12 
Formula weight 428.24 
Temperature (K) 120(2) 
Wavelength (Å) 0.71073 
Crystal System Orthorhombic P 
Space Group Pbca 
Cell Dimensions   
a (Å) 8.9553 
b (Å) 20.5764 
c (Å) 20.8197 j 90.000  90.000  90.000 
Volume 3836.40 
Density 1.483 Mg/m3 
Absorption coefficient 0.371 mm-1 
Crystal size (mm) 0.4 x 0.5 x 0.5 
(sinθ/λ)max (Å-1) 1.0 
Unique reflections 15,821 [R(int) = 0.0183] 
Average redundancy 12.86 
Completeness to (sinθ/λ)max 98.3% 
Absorption correction Empirical (tmin = 0.781, tmax = 0.866) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters 15821 / 0 / 310 
Goodness-or-fit on F2 0.839 
Final R indices [I>2xI R1 = 0.0398 
R indices (all data) R1 = 0.0460, wR2 = 0.1046 
Largest difference peak and trough 1.125 and -0.924  · Å ; 
Nref/Nv 51.04 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 14498 / 0 / 553 
Goodness-or-fit (GoF) on F 4.3321 
Final R indices [I>2xI R1 =0.0280 , wRF = 0.0191 
R indices (all data) R1 = 0.0428  
Largest difference peak and trough 1.586 and -1.328 
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Nref/Nv 26.26 
                           Table 3.1.25 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-Å-1) m (Å3) 
Cl(1) 1.7091E+01 -9.1623E-02 28.5375 
Cl(2) 1.7083E+01 -8.3443E-02 29.2362 
F(1) 9.7141E+00 -7.1410E-01 15.9952 
O(1) 9.0632E+00 -1.0632E+00 13.9309 
O(2) 9.0414E+00 -1.0414E+00 17.0861 
N(1) 7.3505E+00 -3.5052E-01 14.7940 
N(2) 7.0378E+00 -3.7897E-02 13.6417 
N(3) 7.6224E+00 -6.2242E-01 9.3982 
C(1) 6.0326E+00 -3.2683E-02 11.6349 
C(2) 6.0467E+00 -4.6763E-02 12.5226 
C(3) 6.0393E+00 -3.9372E-02 12.3825 
C(4) 6.0361E+00 -3.6164E-02 11.6225 
C(5) 6.0307E+00 -3.0772E-02 11.5925 
C(6) 5.6087E+00 3.9126E-01 8.1997 
C(7) 4.6902E+00 1.3097E+00 5.9674 
C(8) 5.8233E+00 1.7665E-01 9.5862 
C(9) 5.7349E+00 2.6506E-01 8.9042 
C(10) 6.0907E+00 -9.0756E-02 9.7608 
C(11) 6.0831E+00 -8.3101E-02 12.2273 
C(12) 6.0972E+00 -9.7283E-02 11.8901 
C(13) 5.5087E+00 4.9128E-01 8.5226 
C(14) 6.1041E+00 -1.0417E-01 12.4893 
C(15) 6.0730E+00 -7.3067E-02 11.4342 
C(16) 5.7302E+00 2.6979E-01 8.9032 
C(17) 6.0960E+00 -9.6029E-02 12.3126 
C(18) 6.0595E+00 -5.9585E-02 11.8749 
C(19) 6.1013E+00 -1.0138E-01 10.5164 
C(20) 5.9960E+00 3.9506E-03 11.5992 
C(21) 6.0587E+00 -5.8751E-02 10.3359 
H(1) 9.2529E-01 7.4704E-02 6.5207 
H(2) 9.2469E-01 7.5302E-02 6.8181 
H(3) 9.2530E-01 7.4698E-02 7.3475 
H(4) 9.2346E-01 7.6533E-02 6.4552 
H(5) 9.2198E-01 7.8016E-02 7.1033 
H(11) 9.3473E-01 6.5263E-02 6.8992 
H(12) 9.2808E-01 7.1915E-02 6.8045 
H(14) 9.2959E-01 7.0408E-02 6.8216 
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H(15) 9.3330E-01 6.6698E-02 7.1193 
H(17) 9.3349E-01 6.6503E-02 6.1308 
H(18) 9.2584E-01 7.4152E-02 6.5299 
H(20) 9.4419E-01 5.5815E-02 6.4469 
           Table 3.1.26 
Topological Parameters Table: 
Structure Bond Ellipticity ρBCP ρBCP 
Dichlorophenyl Ring  
Inner Carbon Bonds     
 C(16)  -  C(17) 0.20 2.212 -18.806 
C(17)  -  C(18) 0.20 2.207 -19.157 
C(18)  -  C(19) 0.21 2.259 -20.390 
C(19)  -  C(20) 0.17 2.253 -19.937 
C(20)  -  C(21) 0.16 2.219 -19.127 
C(21)  -  C(16) 0.20 2.235 -19.450 
Outer Atom – Inner Carbon Bonds     
 N(3)  -  C(16) 0.05 1.972 -14.549 
H(17)  -  C(17) 0.08 1.846 -19.911 
H(18)  -  C(18) 0.09 1.804 -18.856 
Cl(2)  -  C(19) 0.03 1.338 -0.802 
H(20)  -  C(20) 0.06 1.870 -21.060 
Cl(1)  -  C(21) 0.01 1.339 -0.697 
Monofluorophenyl Ring   
 Inner Bonds     
 C(10)  -  C(11) 0.18 2.175 -18.308 
C(11)  -  C(12) 0.16 2.172 -18.798 
C(12)  -  C(13) 0.18 2.289 -21.566 
C(13)  -  C(14) 0.21 2.291 -22.043 
C(14)  -  C(15) 0.16 2.182 -19.069 
C(15)  -  C(10) 0.20 2.187 -18.872 
Outer Atom – Inner Carbon Bonds     
 C(9)  -  C(10) 0.05 1.897 -14.088 
H(11)  -  C(11) 0.09 1.839 -19.935 
H(12)  -  C(12) 0.08 1.833 -19.664 
F(1)  -  C(13) 0.03 2.083 -18.634 
H(14)  -  C(14) 0.08 1.835 -19.687 
H(15)  -  C(15) 0.09 1.840 -19.952 
Phenyl Ring  
 Inner Carbon Bonds     
 C(6)  -  C(1) 0.23 2.259 -21.059 
C(1)  -  C(2) 0.19 2.202 -20.322 
C(2)  -  C(3) 0.19 2.224 -20.839 
C(3)  -  C(4) 0.16 2.195 -19.618 
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C(4)  -  C(5) 0.19 2.197 -20.204 
C(5)  -  C(6) 0.22 2.253 -20.727 
Outer Atom – Inner Carbon Bonds     
 O(1)  -  C(6) 0.03 1.923 -12.248 
H(1)  -  C(1) 0.05 1.818 -19.063 
H(2)  -  C(2) 0.05 1.815 -19.046 
H(3)  -  C(3) 0.05 1.813 -19.002 
H(4)  -  C(4) 0.05 1.814 -19.012 
H(5)  -  C(5) 0.05 1.818 -19.084 
Ester Linker  
 C(7)  -  C(8) 0.14 1.925 -14.387 
O(1)  -  C(6) 0.03 1.923 -12.248 
O(2)  -  C(7) 0.12 3.249 -46.468 
Triazole Ring   
 N(1)  -  N(2) 0.10 2.928 -16.522 
N(2)  -  N(3) 0.20 2.451 -5.615 
N(3)  -  C(9) 0.18 2.280 -20.969 
C(9)  -  C(8) 0.26 2.215 -19.325 
C(8)  -  N(1) 0.16 2.374 -21.671 
Table 3.1.27 
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Compound 10 
Name: 
HS-P57-4 Molecule A 
propyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate 
Affinity:  
Ki = 4.6 nM ± 0.012 
ORTEP: 
 
Figure 3.1.28 
 
ESP Maps: 
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Figure 3.1.29 
 
  
Figure 3.1.30 
 
Refinement Note: 
 Despite being the most active compound in this set the refinement of HS
problems.  The Moliso program used to perform the global parameter analysis produces errors when 
attempting to calculate the global parameters on this compound.  And no global paramete
been performed on HS-P57-4.  Residual maps are flat.  Contours peak at 2
the C(8A), C(10A), and C(12A) plane.
Crystal Data Table: 
General Sample Information
Molecular formula 
Formula weight 
Temperature (K) 
Wavelength (Å) 
Crystal System 
Space Group 
104 
-P57-4 has several 
 (0.20 
 
 
C18 N3 O2 Cl3 H14 
410.68 
120(2) 
0.71073 
Monoclinic P 
P2(1)/n 
 
 
r analysis has 
) about Cl(1A) in 
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Cell Dimensions   
a (Å) 16.6316 
b (Å) 19.5697 
c (Å) 23.7402 j 90.000  104.256  90.000 
Volume 7488.90 
Density 1.457 Mg/m3 
Absorption coefficient 0.507 mm-1 
Crystal size (mm) 0.25 x 0.5 x 0.5 
(sinθ/λ)max (Å-1) 0.88 
Unique reflections 42,192 [R(int) = 0.0253] 
Average redundancy 15.7 
Completeness to (sinθ/λ)max 98.7% 
Absorption correction Empirical (tmin =0.786, tmax = 0.884) 
Spherical Atom Refinement 
Refinement method Full-matrix least-squares on F2 
Data(I>2xI/restraints/parameters  42,192 / 0 / 1161  
Goodness-or-fit on F2 1.106 
Final R indices [I>2xI R1 = 0.0391 
R indices (all data) R1 = 0.0542, wR2 = 0.1206 
Largest difference peak and trough 1.725 and -1.135  · Å ; 
Nref/Nv 36.34 
Multipole Atom Refinement 
Refinement method Full-matrix least-squares on F 
Data(I>2xI/restraints/parameters 43072 / 0 / 1344 
Goodness-or-fit (GoF) on F 3.606 
Final R indices [I>2xI R1 = 0.0283, wRF = 0.0185 
R indices (all data) R1 = 0.0591  
Largest difference peak and trough 1.094 and -0.893  · Å ; 
Nref/Nv 26.02 
                           Table 3.1.28 
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Atomic Basin Calculations Table: 
Atom e- Population in Basin lm (e-) m (Å3) 
Cl(1A) 1.7068E+01 -6.8143E-02 29.9723 
Cl(2A) 1.7300E+01 -3.0060E-01 30.6826 
Cl(3A) 1.7359E+01 -3.5960E-01 28.7268 
O(1A) 9.0944E+00 -1.0944E+00 12.4969 
O(2A) 9.1560E+00 -1.1560E+00 16.2483 
N(1A) 7.7494E+00 -7.4948E-01 9.1810 
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N(2A) 7.0876E+00 -8.7689E-02 13.6307 
N(3A) 7.3853E+00 -3.8530E-01 13.5932 
C(1A) 5.9521E+00 4.7878E-02 10.3156 
C(2A) 5.6746E+00 3.2536E-01 6.9341 
C(3A) 5.5731E+00 4.2681E-01 6.5375 
C(4A) 4.4028E+00 1.5971E+00 4.4286 
C(5A) 5.8506E+00 1.4931E-01 8.8130 
C(6A) 5.6403E+00 3.5964E-01 8.1647 
C(7A) 6.2276E+00 -2.2761E-01 9.5745 
C(8A) 5.9143E+00 8.5653E-02 10.6106 
C(9A) 6.0484E+00 -4.8485E-02 12.2991 
C(10A) 6.0535E+00 -5.3552E-02 9.8560 
C(11A) 6.06231E+00 -6.2312E-02 11.5515 
C(12A) 5.8787E+00 1.2127E-01 11.2953 
C(13A) 5.8801E+00 1.1987E-01 9.2584 
C(14A) 5.9972E+00 2.7492E-03 10.9010 
C(15A) 6.0554E+00 -5.5451E-02 11.3049 
C(16A) 5.8846E+00 1.1532E-01 8.9336 
C(17A) 6.1459E+00 -1.4598E-01 11.8449 
C(18A) 5.6939E+00 3.0608E-01 8.5002 
H(1A1) 9.9659E-01 3.4000E-03 6.5408 
H(1A2) 9.3871E-01 6.1287E-02 5.9419 
H(1A3) 9.8959E-01 1.0403E-02 6.0989 
H(2A1) 1.0768E+00 -7.6803E-02 6.5437 
H(2A2) 1.0730E+00 -7.3080E-02 7.1586 
H(3A1) 1.0797E+00 -7.9785E-02 6.6019 
H(3A2) 1.0409E+00 -4.0945E-02 6.0628 
H(8A) 9.1904E-01 8.0952E-02 6.2154 
H(9A) 8.9301E-01 1.0698E-01 6.3835 
H(11A) 8.9651E-01 1.0348E-01 6.2504 
H(12A) 9.3263E-01 6.7361E-02 6.3930 
H(14A) 9.2413E-01 7.5869E-02 6.0765 
H(15A) 9.1203E-01 8.7969E-02 6.4179 
H(17A) 9.1313E-01 8.6862E-02 6.5669 
           Table 3.1.29 
Topological Parameters Table: 
Structure Bond Ellipticity ρr ρr 
Dichlorophenyl Ring   
Inner Carbon Bonds     
 C(13A)  -  C(14A) 0.18 2.214 -21.270 
C(14A)  -  C(15A) 0.11 2.124 -18.074 
C(15A)  -  C(16A) 0.14 2.222 -20.429 
C(16A)  -  C(17A) 0.20 2.182 -19.406 
C(17A)  -  C(18A) 0.15 2.251 -22.203 
C(18A)  -  C(13A) 0.20 2.219 -21.137 
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Outer Atom – Inner Carbon Bonds     
 N(1A)  -  C(13A) 0.04 1.948 -14.650 
H(14A)  -  C(14A) 0.04 1.839 -18.253 
H(15A)  -  C(15A) 0.04 1.815 -17.133 
Cl(2A)  -  C(16A) 0.04 1.395 -4.985 
H(17A)  -  C(17A) 0.12 1.805 -17.322 
Cl(3A)  -  C(18A) 0.05 1.410 -3.612 
Monochlorophenyl Ring  
 Inner Carbon Bonds     
 C(7A)  -  C(8A) 0.24 2.101 -17.231 
C(8A)  -  C(9A) 0.19 2.153 -18.743 
C(9A)  -  C(10A) 0.10 2.148 -21.296 
C(10A)  -  C(11A) 0.14 2.206 -19.693 
C(11A)  -  C(12A) 0.16 2.064 -16.552 
C(12A)  -  C(7A) 0.16 2.162 -19.266 
Outer Atom – Inner Carbon Bonds     
 C(6A)  -  C(7A) 0.08 1.839 -13.302 
H(8A)  -  C(8A) 0.09 1.788 -17.455 
H(9A)  -  C(9A) 0.02 1.758 -16.012 
Cl(1A)  -  C(10A) 0.09 1.345 -3.621 
H(11A)  -  C(11A) 0.05 1.770 -17.146 
H(12A)  -  C(12A) 0.04 1.818 -18.628 
Ester Side Chain  
 C(4A)  -  C(5A) 0.15 1.886 -15.030 
O(2A)  -  C(4A) 0.34 2.283 -27.110 
O(1A)  -  C(4A) 0.09 2.283 -27.110 
C(3A)  -  O(1A) 0.04 1.720 -11.248 
H(3A1)  -  C(3A) 0.11 1.897 -17.357 
H(3A2)  -  C(3A) 0.11 1.877 -17.094 
C(2A)  -  C(3A) 0.08 1.740 -12.765 
H(2A1)  -  C(2A) 0.04 1.842 -17.489 
H(2A2)  -  C(2A) 0.04 1.851 -17.516 
C(1A)  -  C(2A) 0.08 1.716 -12.669 
H(1A1)  -  C(1A) 0.27 1.734 -13.259 
H(1A2)  -  C(1A) 0.23 1.712 -10.659 
H(1A3)  -  C(1A) 0.29 1.749 -13.797 
Triazole Ring   
 N(3A)  -  N(2A) 0.14 2.805 -8.063 
N(2A)  -  N(1A) 0.08 2.387 -3.878 
N(1A)  -  C(6A) 0.23 2.324 -22.828 
C(6A)  -  C(5A) 0.26 2.255 -21.930 
C(5A)  -  N(3A) 0.16 2.448 -21.285 
Table 3.1.30 
Global Parameter Analysis 
Molecule Ki (nm) Average Tot Variance Balance V(max) V(min) 
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Deviation  
(e/A) 
(e/A)^2 Parameter 
HS-P53-2 6900 0.0835 0.0218 0.2191 0.171 -0.269 
HS-P53-1 4400 0.1011 0.0287 0.2450 0.373 -0.099 
HS-P57-2 1400 0.1063 0.0338 0.2487 0.365 -0.292 
HS-P226 860 0.1110 0.0333 0.2411 0.192 -0.337 
HS-P69 590 0.1421 0.0713 0.2095 0.389 -0.373 
HS-P183 250 0.0712 0.0173 0.2493 0.213 -0.249 
HS-P57-7 240 0.1022 0.0343 0.2181 0.226 -0.374 
HS-P57-3 180 0.1403 0.0656 0.2489 0.549 -0.385 
AVG-229Ph 170 0.0753 0.0162 0.2324 0.232 -0.193 
HS-P57-4 4.6 n/a n/a n/a n/a n/a 
Table 3.1.31: Global parameter analysis as performed by MolIso.120  Data for HS-P57-4 was not obtainable due to an unresolved program error. 
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Discussion 
 
Part 1: Refinement Quality 
 The final multipole refinement for each molecule varied in quality though there were trends in 
maximum peak and trough residual density values due to similarities in atomic makeup.   All multipole 
refinements were much improved over IAM refinements.  On several occasions the largest residual peak 
and trough for the multipole refinement were greater than that of the corresponding IAM refinement 
for that molecule, as determined by the XDFFT module116 (by performing a fast Fourier transform on the 
residuals) in XD2006, despite having a much lower overall R-factor.  This may be due to the difficulties in 
modeling the electron density of the chlorine atoms in each molecule.  The residual density was minimal 
everywhere except around chlorine atoms where peaks varied from 1 contour (0.10  · Å ;) to the 
extreme of 8 contours (0.80  · Å ;)  in compounds 4 and 8.  On some occasions, the introduction of 
anisotropic-anharmonic temperature factors substantially reduced these residuals.  Chlorine is greater 
in total electron density and thus may be expected to have larger residuals.  Goodness of fit (GoF) values 
for the multipole refinements are increased (of poorer quality) over that of the IAM as no steps were 
taken during weighting to maximize GoF quality as they were with the IAM refinement.   All final 
multipole refinements are considered of suitable quality for this study. 
 Bond critical point values and atomic basin charge calculations were reasonable with the 
exception of a few values.  Compound 1 showed low bond ellipticity in between the carbon bonds of 
nitrogen attached phenyl ring system where high ellipticity is expected.109  Values of the Laplacian of five 
“covalent” bonds are positive (signifying closed shell interactions) where they are expected to be 
negative.99  In all instances these bonds were between carbon and a highly electronegative atom. These 
instances occurred in compound 3 [Cl(2)  -  C(12)], compound 4 [C(1)  -  O(1)], compound 6 [Cl(1)  -  
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C(12)], and compound 7 [Cl(2)  -  C(17)], [Cl(1)  -  C(13)].  Of note is the existence of both slight positively 
and negatively charged chlorine atoms as integrated over their atomic basins.  This occurs on molecules 
with well refined chlorines (low residual density) and does not appear to be an artifact of poor 
refinement.  Otherwise the refined multipole parameters were chemically reasonable. 
Part 2: Analysis of ESP and QTAIM 
 Qualitative and Quantitative analysis of the global surface electrostatic properties of each 
compound ultimately failed show correlation with affinity and statistical parameters of the ESP.  Due to 
a program error, compound 10 (HS-P57-4) could not be analyzed in terms of the surface ESP.  No 
correlation was found between the ESP and Ki of the remaining data.  Furthermore, there were no 
apparent features of the ESP upon visual inspection that indicated greater or lesser Ki values.  No local 
(by atom or ring system) ESP analysis was conducted.   
 Using the R programing language, principal component analysis (PCA) was performed to identify 
variables or combinations of variables that correlate with pharmacological affinity and thus could be 
used to design more potent drugs.121,125-127  The inspected variables consisted of the average aromatic 
ring ellipticity, average aromatic ring carbon bond critical point rho and Laplacian values, position 
specific chlorine charge values, average atomic charge deviation, triazole nitrogen charges, average 
triazole ring charge, carbonyl oxygen and ester oxygen charge, substituent volume, total molecular 
volume,  ring specific and total molecular charge standard deviation (total charge of each molecule is 
zero), average substituent charge, and substituent charge standard deviation.  These variables were 
chosen based on the rimonabant pharmacophore85,86 despite this molecular set having a slightly 
different central ring connectivity.  Correlation was found between the ortho-chlorine charge (ring 1), 
both oxygen sites, substituent volume, total volume, triazole nitrogen, ring 2 rho critical point value, and 
triazol ellipticity (Note: As the two phenyl ring systems on each compound are attached to the central 
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triazole ring, for cross reference purposes ‘ring 1’ refers to the nitrogen attached phenyl ring system in 
the ‘1’ position in compound 1 and ‘ring 2’ refers to the carbon attached phenyl ring system in the 5 
position in compound 1).  Several notes of importance are that for compounds 6 and 4 an extra carbon 
is present before the carbonyl carbon setting it slightly further away from the triazole ring, compound 5 
has a nitrogen in place of the ester oxygen making it a carboxamide, and compound 4 has an alternate 
relative connectivity of the side chain.  An ester functional group and attached substituent are absent in 
compounds 1 and 3.  As they are absent the values (charge and volume) associated with them are set to 
zero.  Due to the range of affinity (Ki = 4.6 nm to 6900 nm) and lack of concentrated data points at the 
far end of the data spectrum (low affinity), only variables that showed a continual trend in correlation or 
anti-correlation when leaving out the most extreme data point for three consecutive data points (Ki = 
6900 nm, 4400 nm, 1400 nm) were considered as correlated or anti-correlated, to ensure correlations 
were not a result of a single extreme data point.  This left seven data points from Ki = 4.6 nm to 860 nm.   
Below are tables of the raw data (Table 4.2.1) and scaled for unit variation and centered data (Table 
4.2.2) for the correlated and anti-correlated data. 
Comp. Ki Ring 1 
Ortho 
Chlorine 
Ring 2 
Rho 
Carbonyl 
Oxygen 
Ester 
Oxygen 
Substituent 
Volume 
Average 
Triazole 
Nitrogen 
Total 
Volume 
Triazole 
Ellipticity 
1 6900 0.0819 2.147 0 0 0 -0.559 299.3423 0.186 
2 4400 0.10925 2.120 -1.1861 -1.0878 28.2821 -0.442 361.4843 0.132 
3 1400 -0.2317 2.198 0 0 0 -0.422 315.8081 0.132 
4 860 0.0787 2.122 -0.9519 -1.1945 43.6581 -0.427 399.2907 0.154 
5 590 -0.1076 2.220 -1.267 -0.7591 132.4619 -0.557 481.4913 0.138 
6 250 -0.0988 2.203 -1.0191 -1.135 44.9406 -0.458 399.3423 0.210 
7 240 0.1071 2.232 -1.1217 -1.1572 124.4466 -0.461 476.3942 0.252 
8 180 -0.304 2.220 -1.4109 -1.0661 43.8547 -0.493 389.9076 0.132 
9 170 -0.0916 2.216 -1.0414 -1.0632 102.1995 -0.337 447.8958 0.180 
10 4.6 -0.3596 2.139 -1.156 -1.0944 68.7358 -0.407 414.9075 0.174 
Table 4.2.1. : Raw data. Maroon variables are correlated.  The more negative the values the greater the affinity.  Dark blue variables are anti-
correlated.  A larger value contributes to greater affinity.  The lone green variable is also anti-correlated.  A less negative value increases 
affinity. 
Comp. Ki Ring 1 
Ortho 
Chlorine 
Ring 2 
Rho 
Carbonyl 
Oxygen 
Ester 
Oxygen 
Substituent 
Volume 
Average 
Triazole 
Nitrogen 
Total 
Volume 
Triazole 
Ellipticity 
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1 2.345 0.9359 -0.781 1.8321 1.8357 -1.2421 -1.5223 -1.6199 0.4265 
2 1.260 1.0924 -1.389 -0.5418 -0.4978 -0.6453 0.2120 -0.6056 -0.9283 
3 -0.043 -0.8588 0.367 1.8321 1.8357 -1.2421 0.5084 -1.3512 -0.9283 
4 -0.278 0.9176 -1.344 -0.0730 -0.7267 -0.3208 0.4343 0.0115 -0.3763 
5 -0.395 -0.1486 0.862 -0.7037 0.2073 1.5533 -1.4927 1.3532 -0.7778 
6 -0.543 -0.0982 0.480 -0.2075 -0.5991 -0.2937 -0.0252 0.0123 1.0286 
7 -0.547 1.0801 1.132 -0.4129 -0.6467 1.3841 -0.0697 1.2700 2.0824 
8 -0.573 -1.2725 0.862 -0.9917 -0.4512 -0.3166 -0.5440 -0.1417 -0.9283 
9 -0.577 -0.0570 0.772 -0.2522 -0.4451 0.9147 1.7684 0.8049 0.2760 
10 2.345 0.9359 -0.781 1.8321 1.8357 -1.2421 0.7308 -1.6120 0.4265 
Table 4.2.2 : Centered and scaled data. Maroon variables are correlated.  The more negative the values the greater the affinity.  Dark blue 
variables are anti-correlated.  A larger value contributes to greater affinity.  The lone green variable is also anti-correlated.  A less negative value 
increases affinity. 
Below are the correlations of each variable with affinity (Ki) from the covariance matrix of the scaled and 
centered data.  
 
Property Correlation with Ki 
Ring 1 Ortho Chlorine 0.5188 
Ring 2 Rho -0.5290 
Carbonyl Oxygen 0.5776 
Ester Oxygen 0.5829 
Substituent Volume -0.5863 
Average Triazole Charge -0.4432 
Triazole N1 Charge -0.5706 
Total Molecular Volume -0.6700 
Triazole Ellipticity* -0.1248 
Table 4.2.2 : Property correlation with Ki. 
 Not all reasons for these property correlations can be clearly understood.  Others, without a 
crystal structure of the binding pocket with an attached ligand, can only be inferred.  Triazole ellipticity 
has been included in this list, although with the most extreme data point from compound 1, the anti-
correlation is approximately a quarter of its anti-correlation if left out.  This persists for leaving out the 
next three most extreme data points and so it has been included (as is the case with all data points 
included).  The more negative the ortho-position chlorine on ring 1 is, the more it contributes to 
increased affinity (lower Ki).  As it is assumed to bind in a similar fashion as rimonabant, this feature of 
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the compound would come in close contact with a phenylalanine residue of the receptor.85  It can be 
speculated that attractive interactions occur with other surrounding residues or positive amine groups.  
Both oxygen sites are in proximity to features suspected of stabilizing an Asp366-Lys192 salt bridge via 
hydrogen bonding.86  More negative oxygens are shown to increase affinity.  The ester substituent, 
according to the rimonabant pharmacophore, is positioned to interact with hydrophobic segments of 
the binding pocket.86  Larger ester substituents, assuming hydrophobicity of the substituent, contributes 
to an increase in affinity made possible by providing more hydrophobic interactions.  The same 
argument can be made for the total molecular volume which has a slightly greater correlation than the 
substituent volume.  There is a general negative correlation of the average charge of the triazole 
nitrogens charge with affinity at -0.44.  The most exposed nitrogen (in the 3 position in compound 1 
referred to as N1) had an even more negative correlation at -0.57.  This may indicate that it is better for 
a compound to be charge neutral. 
Plots of the scaled and centered data are in the figures below. 
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Figure 4.2.1.: Ortho-Chlorine charge on ring 1 vs Ki.  Fit: slope = 0.5188, R
2 = 0.2690.  
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Figure 4.2.2.: Ring 2 average carbon-carbon rho bond critical point vs Ki. Fit: slope = -0.5300, R
2 = 0.2798. 
  
Figure 4.2.3.: Substituent carbonyl oxygen charge vs Ki. Fit: slope = 0.5776, R
2 = 0.3337. 
  
Figure 4.2.4.: Substituent ester oxygen charge vs Ki. Fit: slope = 0.5829, R
2 = 0.3398. 
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Figure 4.2.5.: Substituent volume vs Ki.  Fit:  slope = -0.5863, R
2 = 0.3437. 
 
 Figure 4.2.6.: Triazole N1 charge vs Ki.  Fit: slope = -0.4432, R2 = 0.2000. 
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Figure 4.2.6.: Triazole N1 charge vs Ki.  Fit: slope = -0.5706, R
2 = 0.3255. 
 
 Figure 4.2.7.: Molecular volume vs Ki.  Fit: slope = -0.6999, R
2 = 0.4899. 
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 R-squared values are relatively high, as there are multiple contributing factors to affinity, and R-
squared is an indicator of variance in the data unaccounted for by the linear fit.130  Outliers that are in 
extreme with or against the trend in one graph often can be explained by data in others.  Correlations 
were not weighted and a scored model was not generated.  In order to reduce the dimensionality of the 
data, principal component analysis was conducted.125  The biplots (a plot that includes both the 
parameters and measurements) in figures 4.2.8 and 4.2.9 show a graphic representation of correlation 
and molecular similarity.  An attempt was made to interpret the data including only the first three 
principal components (PC1 [43.66%], PC2 [22.58%], PC3 [13.19%]) which accounts for a total of 80.14% 
of the variation in the data.  The principal components are the Eigen vectors of the covariance matrix.  
The three principal components that account for the greatest amount of variation were chosen.  This is 
determined by solving for the Eigen values by singular value decomposition.125  The total variance of the 
data is the sum of all Eigen values.  And the percent of variation taken into account by a single principal 
component is its associated Eigen value divided by the sum of all Eigen values times one hundred.   The 
analysis reconfirms what is expressed in the correlation matrices.  In the future data mining techniques 
that explore in greater detail correlation and co-correlation may be applied to the model generated.  
The model’s effectiveness may be increased by adding observed variables that were not correlated with 
Ki but would have to be scrutinized in the same fashion as the included data.  This would offer the 
advantage of obtaining information on how to alter features about the molecule that would affect other 
features correlated strongly with Ki but not necessarily as correlated with Ki themselves.  Below are 
projections of the data onto the first and second principal components, and the second and third 
principal components. 
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Figure 4.2.8.: Biplot of data onto principal components 1 & 2 with percentages of variation accounted for by each axis.  The red vectors 
represent variable.  Those vectors that point in the same direction are correlated.  Those that point way from each other are anti-correlated.  
Where each molecule is labeled on the plot shows its similarity or dissimilarity with the rest.  The closer a molecules point is to a vector, the 
greater its value of the associated variable is. 
 
 
 
120 
 
  
Figure 4.2.9.: Biplot of data onto principal components 2 & 3 with percentages of variation accounted for by each axis.  The red vectors 
represent variable.  Those vectors that point in the same direction are correlated.  Those that point way from each other are anti-correlated.  
Where each molecule is labeled on the plot shows its similarity or dissimilarity with the rest.  The closer a molecules point is to a vector, the 
greater its value of the associated variable is. 
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Conclusion 
 In conclusion, ten x-ray charge density studies were performed on CB1 receptor 
antagonist of similar structure.  Properties derived from the study were analyzed in an attempt to 
correlate them with measured CB1 binding affinity.  These properties included: the magnitude of 
the electron density at the bond critical points deemed relevant, the magnitude of the Laplacian 
of the electron density at the bond critical points deemed relevant, average bond ellipticity of 
moieties of each molecule, the molecular volume, the charge of atoms of functional groups, the 
average charge of the triazole ring, the volume of specific moieties, and the electrostatic potential 
(global statistical analysis). 
 Correlations/anti-correlations were found between affinity and the triazole nitrogen 
charges, oxygen charges of the ester functional groups, substituent volumes, molecular volumes, 
ring 1 ortho-chlorine charges, and ring 2 rho bond critical point values.  Using principal 
component analysis, the first three principal components were found to account for 83.9% of the 
variance in the values.  It has been determined that more negative oxygen charges as well as 
ortho-chlorine charges, and larger substituent and molecular volumes increases affinity.  While 
increased nitrogen charges reduces affinity.  With this information it may be possible to further 
refine CB1 antagonist affinity.  Negatively charged nitrogen atoms may be substituted with 
carbon atoms, and less negatively charged atoms may be placed where specified chlorines are, 
etc.   
In the future it may be a better approach to use invarioms131,132, an approach that models 
computed electron density out the next nearest neighbor with the Hansen-Coppens multipole 
formalism and superimposes the resulting multipoles onto equivalent atoms, to estimate electron 
densities as this would allow for a larger sample of molecules to be used in the analysis.  This 
would also decrease the resolution needed to perform the analysis and limit the amount of effort 
required to obtain adequate resolution of data.  Also generating a weighting scheme and scoring 
the model produced is preferable, though it was not performed here. 
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